



---

# Drug Information Update

April 2018

## TABLE OF CONTENTS

---

NEWLY AVAILABLE GENERICS .....	2
NEW DRUG ENTITIES/COMBINATIONS/STRENGTHS .....	3
NEW INDICATIONS (EXISTING DRUGS).....	5
FDA NEWS/BULLETINS/ADVISORIES/SAFETY ALERTS .....	7
STUDIES AND RECENT TOPICS.....	8
RECALLS.....	11
CURRENT DRUG SHORTAGES.....	20

## NEWLY AVAILABLE GENERICS

---

GENERIC DRUG NAME	STRENGTH & DOSAGE FORM	GENERIC MANUFACTURER	BRAND NAME
PALONOSETRON HCL	0.25 mg/5 mL	TEVA	ALOXI
UREA	41% CREAM	METHOD PHARMACEUTICAL	UTOPIC
SELENIUM SULFIDE	2.30% SHAMPOO	METHOD PHARMACEUTICAL	SELRX
DICLOFENAC SODIUM/CAPSAICIN	1.5%-0.025% KIT CR-SOL	NUCARE PHARMACEUTICALS	NUDICLO
DICLOFENAC SODIUM/CAPSAICIN	75 mg-0.025 KIT	NUCARE PHARMACEUTICALS	NUDICLO

## NEW DRUG ENTITIES/COMBINATIONS/STRENGTHS

DESCRIPTION	BRAND NAME	GENERIC NAME	STRENGTH	NOTES
ANTIHYPERLIPIDEMIC - HMG COA REDUCTASE INHIBITORS	ZYPITAMAG	PITAVASTATIN MAGNESIUM	1 MG	New Entity, no pricing, claims will not adjudicate until pricing is added
ANTIHYPERLIPIDEMIC - HMG COA REDUCTASE INHIBITORS	ZYPITAMAG	PITAVASTATIN MAGNESIUM	2 MG	New Entity, no pricing, claims will not adjudicate until pricing is added
ANTIHYPERLIPIDEMIC - HMG COA REDUCTASE INHIBITORS	ZYPITAMAG	PITAVASTATIN MAGNESIUM	4 MG	New Entity, no pricing, claims will not adjudicate until pricing is added
THROMBOLYTIC ENZYMES	TNKASE	TENECTEPLASE	50 MG	New Dosage Form, no pricing, claims will not adjudicate until pricing is added
ANTIRETROVIRAL - ANTI-CD4 DOMAIN 2 MONOCLONAL AB	TROGARZO	IBALIZUMAB-UIYK	200MG/1.33	New Entity
ANTIHYPERLIPIDEMIC - HMG COA REDUCTASE INHIBITORS	ZYPITAMAG	PITAVASTATIN MAGNESIUM	1 MG	New Entity, no pricing, claims will not adjudicate until pricing is added
ANTIHYPERLIPIDEMIC - HMG COA REDUCTASE INHIBITORS	ZYPITAMAG	PITAVASTATIN MAGNESIUM	2 MG	New Entity, no pricing, claims will not adjudicate until pricing is added
VITAMIN C PREPARATIONS	ASCOR	ASCORBATE SODIUM	500 MG/ML IV SOL	New Strength
MIOTICS AND OTHER INTRAOCULAR PRESSURE REDUCERS	RHOPRESSA	NETARSUDIL MESYLATE	0.02 % OPTH. SOL.	New Combination, no pricing, claims will not adjudicate until pricing is added
ANTINEOPLASTIC SYSTEMIC ENZYME INHIBITORS	TASIGNA	NILOTINIB HCL	50 MG	New Strength
OPHTH. VEGF-A RECEPTOR ANTAG. RCMB MC ANTIBODY	LUCENTIS	RANIBIZUMAB	0.3MG/0.05	New Strength
ANTIVIRALS, HIV-SPEC, NUCLEOSIDE-NUCLEOTIDE ANALOG	CIMDUO	LAMIVUDINE/T ENOFOVIR DISOP FUM	300-300 MG	New Combination

DESCRIPTION	BRAND NAME	GENERIC NAME	STRENGTH	NOTES
ARTV NUCLEOSIDE,NUCLEOTIDE, NON-NUCLEOSIDE RTI COMB	SYMFI	EFAVIRENZ/LA MIVU/TENOFO V DISOP	600-300MG	New Strength
INSULINS	TOUJEO MAX SOLOSTAR	INSULIN GLARGINE,HU M.REC.ANLOG	300/ML (3)	New Pen Volume (3 mL)
PROTON-PUMP INHIBITORS	ESOMEPE-EZS	ESOMEPAZOL E MAG/GLYCERIN	20 MG	New Combination
GLUCOCORTICIDS	TRIAMCINOLO NE ACETONIDE	TRIAMCINOLO NE ACET/0.9%NAC L/PF	40 MG/ML	New Combination
GLUCOCORTICIDS	TRIAMCINOLO NE ACET- BUPIVACAINE	TRIAMCINOLO NE/BUPIVACAI NE/NACL	40-5 MG/ML	New Combination
EYE ANTI-INFLAMMATORY AGENTS	PREDNISOLON E- BROMFENAC	PREDNISOLONE ACETATE/BRO MFENAC	1 %-0.075%	New Combination

## NEW INDICATIONS (EXISTING DRUGS)

---

### Afinitor DISPERZ<sup>®</sup>

**April 10, 2018**

Novartis today announced that the US Food and Drug Administration (FDA) has approved Afinitor DISPERZ<sup>®</sup> (everolimus tablets for oral suspension), for the adjunctive treatment of adult and pediatric patients aged two years and older with tuberous sclerosis complex (TSC)-associated partial-onset seizures. Afinitor DISPERZ is now the first approved pharmacologic therapy in the US specifically indicated for the treatment of this condition.

Source: Novartis

### Hizentra<sup>®</sup>

**March 16, 2018**

Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) approved Hizentra<sup>®</sup> (Immune Globulin Subcutaneous [Human] 20% Liquid) as the first and only subcutaneous immunoglobulin (SCIg) for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment. The approval was based on data from the Phase III PATH (Polyneuropathy and Treatment with Hizentra) study, which is the largest controlled clinical study in CIDP patients to date. CIDP is a rare autoimmune disorder that affects the peripheral nerves and may cause permanent nerve damage.

Source: CSL Behring

### Rubraca<sup>®</sup>

**April, 6, 2018**

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced that the U.S. Food and Drug Administration (FDA) has approved Rubraca<sup>®</sup> (rucaparib) tablets for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication. Warnings and precautions include Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), and embryo-fetal toxicity. Please see warnings and precautions and additional

Source: Clovis Oncology, Inc.

### Bydureon<sup>®</sup>

**April 3, 2018**

AstraZeneca today announced the US Food and Drug Administration (FDA) has approved BYDUREON<sup>®</sup> (exenatide extended-release) for injectable suspension as an add-on therapy to basal insulin in adults with type 2 diabetes (T2D) with inadequate glycemic control. BYDUREON is approved for adults with T2D whose blood sugar remains uncontrolled on one or more antidiabetic medicines in addition to diet and exercise, to improve glycemic control.

Source: AstraZeneca

### **Blincyto<sup>®</sup>**

**March, 29, 2018**

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BLINCYTO<sup>®</sup> (blinatumomab) for the treatment of adults and children with B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1 percent. This indication is approved under accelerated approval based on MRD response rate and hematological relapse-free survival (RFS). Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. BLINCYTO, the first-and-only approved bispecific CD19-directed CD3 T cell engager (BiTE<sup>®</sup>) immunotherapy, is now also the first-and-only therapy to be FDA-approved for MRD.

Source: Amgen

### **Toujeo<sup>®</sup> Max SoloStar<sup>®</sup>**

**March, 27, 2018**

The U.S. Food and Drug Administration (FDA) approved Sanofi's Toujeo<sup>®</sup> (insulin glargine 300 Units/mL) Max SoloStar<sup>®</sup>, the highest capacity long-acting insulin pen that will be available on the market. The new Max SoloStar pen holds 900 Units of Toujeo, more than any other long-acting insulin pen in the U.S., and provides up to 160 Units/mL of Toujeo in a single injection.

Source: Sanofi

### **Tasigna<sup>®</sup>**

**March 22, 2018**

Novartis announced today that the US Food and Drug Administration (FDA) expanded the indication for Tasigna<sup>®</sup> (nilotinib) to include treatment of first- and second-line pediatric patients one year of age or older with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP).

Source: Novartis

## FDA NEWS/BULLETINS/ADVISORIES/SAFETY ALERTS

---

### MedWatch - Coastal Meds Recall of All Products Marketed as Sterile

[Posted 4/13/2018]

**ISSUE:** FDA is alerting health care professionals to a voluntary recall of all non-expired products marketed as sterile made by Coastal Meds due to visible particles in some of the drug vials for injection.

**BACKGROUND:** During FDA's recent inspection of Coastal Meds, investigators observed visible particulates and poor sterile production practices which further raise concerns about particulates in Coastal Meds' drug products intended for injection. On April 5, 2018, Coastal Meds initiated a voluntarily recall of all products intended to be sterile. FDA requested the compounder inform the public, but they have not done so. Therefore, FDA is alerting health care professionals to dispose of and not administer sterile drug products intended for injection that were produced and distributed by Coastal Meds.

**RECOMMENDATION:** Health care professionals should immediately check their medical supplies, quarantine any sterile drug products intended for injection from Coastal Meds, and not administer them to patients. Health care professionals should make alternative arrangements to obtain any medications they administer to patients from reliable sources that adhere to proper quality standards.

Source: U.S. Food and Drug Administration (FDA)



## STUDIES AND RECENT TOPICS

---

### [GW cannabis-derived epilepsy drug gets positive FDA staff review](#)

**April 17, 2018**

GW Pharmaceuticals' cannabis-derived medicine for severe childhood epilepsy won a favorable review from U.S. Food and Drug Administration (FDA) staff on Tuesday, boosting hopes for its approval in the world's biggest drugs market.

Source: reuters.com

### [Metformin and Statin-Induced Myopathies: Potential Adherence Booster?](#)

**April 16, 2018**

Despite ample evidence supporting statin use to lower cholesterol, and reduce risks for coronary heart disease, some patients hesitate to take them or experience muscular adverse effects. The latter—statin-induced myopathies—are a main cause of nonadherence, which leads to insufficient cardiovascular risk reduction.

Source: pharmacytimes.com

### [First medical marijuana pharmacy in New Orleans area gets permit approved](#)

**April 16, 2018**

The state Pharmacy Board on Tuesday (April 16) selected New Orleans pharmacist Ruston Henry of H&W Drug store, Inc., to operate one of the first medical marijuana pharmacies in Louisiana. The decision followed several hours of testimony from five applicants vying for the permit for Region 1, which includes the New Orleans area.

Source: nola.com

### [Hepatitis C Drugs Can Cost \\$84,000. This New One May Be Just As Good—But Cost \\$300](#)

**April 12, 2018**

Striking advances in hepatitis C drug development over the past five years have made the infectious, liver-wasting viral disease a curable one—if you can afford the drugs.

Made by companies like Gilead, AbbVie, Merck, and others, drugs that treat the disease are listed at tens of thousands of dollars in the U.S. But a nonprofit is making its own hepatitis C combination medication that it says is just as effective as those created by for-profit drug giants. And it could cost just \$300 for 12 weeks of treatment in poor nations like Malaysia.

Source: fortune.com

**FDA Grants Dacomitinib a Priority Review for Lung Cancer Treatment****April 04, 2018**

The Food and Drug Administration (FDA) granted priority review to dacomitinib for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR-activating mutations, according to Pfizer, the drug's manufacturer.

Source: curetoday.com

**Facebook and Twitter Pushed to Do More to Halt Online Opioid Sales****April 4, 2018**

The top U.S. drug regulator wants social-media sites including Facebook Inc. and Twitter Inc. to do more to stop illegal online sales of opioids that are contributing to hundreds of thousands of overdose deaths. Food and Drug Administration Commissioner Scott Gottlieb is expected to say in a speech on Wednesday that social-media companies and internet-service providers need to be more proactive in rooting out sales pitches for addictive painkillers. He said that while the platforms are reluctant to police content the ads are "insidious threats."

Source: bloomberg.com

**Opioid Use Lower in States That Eased Marijuana Laws****April 2, 2018**

Medical marijuana appears to have put a dent in the opioid abuse epidemic, according to two studies published Monday. The research suggests that some people turn to marijuana as a way to treat their pain, and by so doing, avoid more dangerous addictive drugs. The findings are the latest to lend support to the idea that some people are willing to substitute marijuana for opioids and other prescription drugs.

Source: npr.org

**FDA launches mobile app to improve access to information about drugs****March 26, 2018**

On Feb. 22, the FDA issued a safety announcement ([www.fda.gov](http://www.fda.gov)) on prescribing clarithromycin (Biaxin) to patients with heart disease because of an increase in the risk of cardiac and cerebrovascular events and even death that can occur years later. This recommendation is based on the FDA's review of 10 years of follow-up data ([www.ctu.dk](http://www.ctu.dk)) from the large CLARICOR clinical trial ([www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)) involving short-term clarithromycin use in patients with stable coronary heart disease. It was during that initial placebo-controlled trial that these adverse events were first observed.

Source: healio.com

**Albuterol Less Effective in Minority Children for Genetic Reasons**

**March 25, 2018**

New research is shedding light on the genetic reasons albuterol doesn't seem to work as well against asthma in minority children. Researchers from the University of California, San Francisco, have completed a whole-genome sequencing study specifically looking at asthma drug response in minority children. The study looked at the genomes of 1441 children across a diverse range of ethnic backgrounds. Each of the children in the study had either a very high or a very low response to albuterol.

Source: [mdmag.com](http://mdmag.com)

## RECALLS

Product Type	Product Description	Class	Code Info	Reason for Recall	Recalling Firm
Drugs	Red Zone Xtreme 3000 Capsules, Dietary Supplement Product, 1 count blister pack, UPC 8 91656 00200 9, Exp Date 12/31/2021	Class I	UPC # 8916560022 09, exp date 12/31/2021	Marketed without an Approved NDA/ANDA; FDA analysis found this product to contain undeclared Tadalafil, an FDA approved drug for the treatment of erectile dysfunction.	Jimmy Weber
Drugs	DELFLEX Peritoneal Dialysis Solution, 2.5% Low Mg/Low Ca Single Bag, packaged in a) 3L (4 pack, NDC 49230-209-30), b) 2 L (6 pack NDC 49230-209-23), Rx only, Fresenius Medical Care NA, Waltham, MA 02451.	Class II	Lot #: a) 17KU03006, 7KU03007; b) 17KU03004, 17KU03005, Exp.08/2019	Lack of Assurance of Sterility: Leakage of the peritoneal dialysis (PD) solution bag.	Fresenius Medical Care Renal Therapies Group, LLC
Drugs	Estradiol Vaginal Inserts, USP 10 mcg, packaged in a) 8 inserts/carton (NDC 0093-3223-08) and b) 18 inserts/carton (NDC 0093-3223-97), Rx only, Teva Women's Health, Inc. Subsidiary of Teva Pharmaceuticals USA, North Wales, PA 19454.	Class II	Lot #: a) 33812545A, 33812546A, 33812774A, Exp. 12/2018; 33812775A, Exp. 01/2019; 33812776A, 33812777A, Exp. 05/2019; 33813786A, 33813868A, Exp. 7/2019; 33813974A, 33814058A, Exp. 09/2019;	Defective Container: This recall is being initiated due to product complaints regarding difficulty in dispensing the tablet from the applicator.	Teva Pharmaceuticals USA

Product Type	Product Description	Class	Code Info	Reason for Recall	Recalling Firm
			33814113A, Exp. 01/2019; b) 33812547A, 33813361A, 33813676A, Exp. 1/2019		
Drugs	Evamist (estradiol transdermal spray), 1.53mg estradiol/spray, 0.27 fl oz (8.1 mL) per bottle, Rx Only, Manufactured for Perrigo, Minneapolis, MN 55427. NDC: 0574-2067-27	Class II	Lot: MEEF Exp. 04/2020	Defective Delivery System: Potential that cracks in the vial neck near the crimp may result in product evaporation and/or leaking and the inability to properly dispense product.	Paddock Laboratories, LLC.
Drugs	E-Z-Paste Barium Sulfate Esophageal Cream (60% w/w), 454 g tube, Rx only, Manufactured by E-Z-EM Canada Inc. for E-Z-EM Inc. a subsidiary of Bracco Diagnostics Inc., Monroe Twp., NJ 0883, NDC 32909-770-01	Class II	Lot # 00538529	Failed stability specifications: Out-of-specification (OOS) result for a preservative assay - methylparaben - during stability testing of one lot.	Bracco Diagnostics Inc.
Drugs	Vancomycin 1g added to 250mL of 0.9% Sodium Chloride IV bag, Rx only, APOLLOcare, 3801 Mojave Ct., Suite 101, Columbia, MO 65202, NDC 71170-254-25.	Class II	Lot#: AC-015565, Exp. 03/26/2018	Stability Data Does Not Support Expiry: 90-day beyond use date (BUD) for the affected product is not supported.	Apollo Care

Product Type	Product Description	Class	Code Info	Reason for Recall	Recalling Firm
Drugs	Vancomycin 1.25g added to 250 mL of 0.9% Sodium Chloride IV bag, Rx only, APOLLOcare, 3801 Mojave Ct., Suite 101, Columbia, MO 65202, NDC 71170-254-25.	Class II	Lot#: AC-015569, Exp. 03/26/2018	Stability Data Does Not Support Expiry: 90-day beyond use date (BUD) for the affected product is not supported.	Apollo Care
Drugs	Fosphenytoin Sodium Injection, USP 500 mg PE*/10 mL, Made in India. Distributed by: Amneal Biosciences, Bridgewater, NJ 08807, NDC 70121-1390-1	Class II	Lot #: AP160022, AP160023, Exp. 05/2018; AP16038, AP160039, AP160040, Exp. 06/2018; AP160076, AP160077, AP160078, Exp. 12/2018	Presence of particulate matter	Amneal Pharmaceuticals
Drugs	Conzerol zero molluscum contagiosum, Topical Cream, Net weight 0.78 (22g), Elrose Labs, Sanford FL 32771 USA --- NDC 70223-001-06	Class II	All product within expiry	cGMP Deviations	Elrose labs Inc.
Drugs	Molleave, 2 oz bottle, OTC, Manufactured for Elrose Labs, Inc.	Class II	All product within expiry	cGMP Deviations	Elrose labs Inc.

Product Type	Product Description	Class	Code Info	Reason for Recall	Recalling Firm
Drugs	Conzerol (antipoxin) H2O2 Gel, Hydrogen Peroxide Gel 3%, 1.5 oz. tube, OTC, Manufactured for Elrose Labs, Inc., Sanford, FL	Class II	All product within expiry	cGMP Deviations	Elrose labs Inc.
Drugs	Zhong Hua Jiu (menthol 1%) Patch, Distributed by United Pacific Company, UPC 6 924938 100226, NDC 53614-001-02	Class II	Lot #:14122921, Exp.12/30/2019, 15091512, Exp. 9/15/2020, 6032321, Exp. 3/23/2021, 17030921, Exp. 3/09/2022	CGMP Deviations: the product was produced with substandard GMP manufacturing processes.	United Pacific Co Ltd
Drugs	Brilliant Blue G for Intraocular Injection 0.5mL vial 0.25 mg/mL Compounded by: Pine Pharmaceuticals 355 Riverwalk Pkwy Tonawanda, NY 14150. NDC 69194-0358-01	Class III	Lot#: 18098@1, Exp. 7/16/2018	Labeling: Label Mix-Up: Brilliant Blue G was labeled with an inaccurate auxiliary label which contained active/inactive ingredient information for incorrect product.	Pine Pharmaceuticals, LLC
Drugs	Triamcinolone Acetonide Lotion, USP 0.1%, 60 mL bottle, Rx Only, Marketed by: VersaPharm Incorporated, Marietta, GA 30062; Manufactured by: Ei LLC, Kannapolis, NC 28083, NDC	Class III	Lot# 2062900, Exp 05/18	Failed Impurities/Degradation Specifications: High out of specification results for an impurity.	Akorn, Inc.

Product Type	Product Description	Class	Code Info	Reason for Recall	Recalling Firm
	61748-220-60.				
Drugs	Fluconazole Injection, USP 200 mg in in 100 mL (2 mg/mL), 10 Single Dose Flexible Containers, Rx Only, Manufactured for: Claris Lifesciences, Inc. North Brunswick, NJ 08902 By; Claris Injectables Ltd. Gujarat, India --- NDC 36000-006-10	Class III	Lot A060644, May 2018	Superpotent and Failed Stability Specifications; out of specification results for assay and water vapor permeability	Renaissance Lakewood, LLC
Drugs	Indomethacin Capsules USP, 50 mg, 100-count bottle, Rx Only, Manufactured by: Glenmark Pharmaceuticals Ltd., Colvale-Bardez, Goa 403513, India; Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430, NDC 68462-302-01.	Class III	Lot #: 19172776, 19172794, Exp 07/19; 19173111, 19173186, 19173188, 19173189, Exp 08/19; 19173852, 19173878, 19173893, Exp 10/19; 19174318, 19174341, Exp 11/19.	Labeling: Incorrect Instructions: bottles incorrectly labeled with the usual adult dosage of "One or two capsules 2 or 3 times a day." rather than the correct usual adult dosage of "One capsule 2 or 3 times a day.	Glenmark Pharmaceuticals Inc., USA
Drugs	Chlorhexidine Gluconate Oral Rinse, 0.12%, 15 mL unit dose cups (NDC 50383-720-15) packaged in 100-count (10 x 10) cups per case pack	Class III	Lot #: 350836, Exp 05/18	Subpotent Drug: Product crystallization with accompanying low out of specification results for chlorhexidine assay.	Akorn, Inc.



Product Type	Product Description	Class	Code Info	Reason for Recall	Recalling Firm
	(NDC 50383-720-18 or 50383-720-19), Rx Only, Hi-Tech Pharmacal Co., Inc., Amityville, NY 11701.				
Drugs	24-HOUR Oral Care q2 Kit with Ballard* Technology, containing 2 Toothbrush Packs with CHG Solution, Chlorhexidine Gluconate Oral Rinse, 0.12%, 15 mL unit dose cup (NDC 50383-720-15), Rx Only, Hi-Tech Pharmacal Co., Inc. Amityville, NY 11701; Kit Manufactured by Halyard Health, Inc., 5405 Windward Parkway, Alpharetta, GA 30004; Distributed in the USA by Halyard Sales, LLC, Alpharetta, GA 30004, Product 97012.	Class III	Chlorhexidine Gluconate Oral Rinse lot # 350836, Exp 05/18 contained within kit lot #: 0202511399 , 0202511400 , 0202543553 , Exp 03/18; 0202518977 , 0202538282 , 0202538283 , 0202538284 , 0202538285 , 0202543552 , 0202642220 , 0202642224 , 0202642225 , Exp 04/18	Subpotent Drug: Product crystallization with accompanying low out of specification results for chlorhexidine assay.	Akorn, Inc.
Drugs	24-HOUR Oral Care q4 Kit with Ballard* Technology, containing 2 Toothbrush Packs	Class III	Chlorhexidine Gluconate Oral Rinse lot # 350836, Exp	Subpotent Drug: Product crystallization with accompanying low out of specification results for chlorhexidine assay.	Akorn, Inc.

Product Type	Product Description	Class	Code Info	Reason for Recall	Recalling Firm
	with CHG Solution, Chlorhexidine Gluconate Oral Rinse, 0.12%, 15 mL unit dose cup (NDC 50383-720-15), Rx Only, Hi-Tech Pharmacal Co., Inc. Amityville, NY 11701; Kit Manufactured by Halyard Health, Inc., 5405 Windward Parkway, Alpharetta, GA 30004; Distributed in the USA by Halyard Sales, LLC, Alpharetta, GA 30004, Product 97014.		05/18 contained within kit lot #: 0202522468 , 0202522470 , Exp 03/18; 0202518966 , 0202522469 , 0202522471 , 0202533449 , 0202533456 , 0202533463 , 0202543351 , 0202548200 , Exp 04/18		
Drugs	buPROPion HCl Extended-Release Tablets, USP (SR), 100 mg, 60 count bottles, Rx Only, Manufactured for: Cipla USA Inc. 1560 Sawgrass Corporate Parkway Suite 130 Sunrise, FL 33323, Manufactured by: InvaGen Pharmaceuticals, Inc. (a subsidiary of Cipla Ltd.) Hauppauge, NY 11788 --- NDC 69097-877-03	Class III	Lot# I1606579 and Lot# I1606580 Exp: 05/2018; Lot# I1612114 and Lot# I1612115 Exp: 11/2018	Failed Dissolution Specifications; during stability testing	InvaGen Pharmaceuticals, Inc.

Product Type	Product Description	Class	Code Info	Reason for Recall	Recalling Firm
Drugs	buPROPion HCl Extended-Release Tablets, USP (SR), 150 mg ,a) 60 count (NDC 69097-878-03) and b) 100 count (NDC 69097-878-07) bottles, Rx Only, Manufactured for: Cipla USA Inc. 1560 Sawgrass Corporate Parkway Suite 130 Sunrise, FL 33323, Manufactured by: InvaGen Pharmaceuticals, Inc. (a subsidiary of Cipla Ltd.) Hauppauge, NY 11788	Class III	a) Lot I1606609 and Lot I1606610 Exp. Date 05/2018; Lot I1610639 Exp. Date 09/2018 b) Lot #I1606610 Exp Date 05/2018; Lot I1607847 and Lot I1607845 Exp Date 06/2018; Lot I1610639 Exp Date 09/2018	Failed Dissolution Specifications; during stability testing	InvaGen Pharmaceuticals, Inc.
Drugs	Fabior (tazarotene) Foam, 0.1%, 100 grams can, Rx only, Distributed by: Mayne Pharma, Greenville, NC 27834; NDC 51862-295-10.	Class III	Lot: MBEB, Exp. 01/31/2019	Superpotent Drug: High out of specification results for tazarotene assay at the 9-month stability time point.	Mayne Pharma Inc
Drugs	Tramadol Hydrochloride 50 mg tablets, 120-count, Rx Only; Distributed by Quality Care Products, Temperance, MI 48182 Mfr. CSPC Ouyi Pharm Co., Ltd. Shijazhuang, Hebei, China; NDC	Class III	Lot # 116289, Exp. 09/20	Labeling: Incorrect or Missing Lot and/or Exp Date	Lake Erie Medical & Surgical Supply Inc

Product Type	Product Description	Class	Code Info	Reason for Recall	Recalling Firm
	55700-0412-01				
Drugs	Decitabine for Injection, 50mg per vial, Rx only, Manufactured by: Cipla Ltd., Verna Goa, India, Manufactured for: Cipla USA, Inc., 1560 Sawgrass Corporate Parkway, Suite 130, Sunrise, FL 33323, NDC 69097-285-37	Not Yet Classified	Lot #: GE70493, GE70502, GE70512, Exp 8/2019	Failed impurities/degradation specifications: Failure to water content and impurity	InvaGen Pharmaceuticals, Inc.

## CURRENT DRUG SHORTAGES

---

### Thiamine Injection

**April 23, 2018**

#### Reason for the Shortage

- Fresenius Kabi had thiamine injection on shortage due to short-term manufacturing delays.
- Mylan Institutional did not provide a reason for the shortage.

#### Estimated Resupply Dates

- Fresenius Kabi has thiamine 100 mg/mL 2 mL vials on back order and the company estimates a release date of early-May 2018.
- Mylan Institutional has thiamine 100 mg/mL 2 mL vials on back order and the company estimates a release date of early-May 2018.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=387>

### Nalbuphine Injection

**April 23, 2018**

#### Reason for the Shortage

- Pfizer has nalbuphine on shortage due to manufacturing delays.

#### Estimated Resupply Dates

- Pfizer has nalbuphine 10 mg/mL 1 mL ampules on back order and the company estimates a release date of May 2018. The 10 mg/mL 10 mL vials are available in limited supply. The 20 mg/mL 1 mL ampules are on back order and the company estimates a release date of July 2018.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=409>

### Methylphenidate Extended-Release Oral Suspension and Chewable Tablets

**April 23, 2018**

#### Reason for the Shortage

- Pfizer has Quillivant XR on shortage due to manufacturing delays.
- Pfizer has QuillChew ER chewable tablets available.

#### Estimated Resupply Dates

- Pfizer has Quillivant XR 5 mg/mL extended-release oral suspension in 60 mL bottles on back order and the company estimates a release date of June 2018.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=373>

### Leucovorin Calcium Injection

**April 23, 2018**

#### Reason for the Shortage

- Fresenius Kabi has leucovorin available.
- Sagent had leucovorin on shortage due to manufacturing delay.

- Teva has leucovorin available.
- West-Ward did not provide a reason for the current shortage.

#### Estimated Resupply Dates

- Fresenius Kabi has leucovorin 200 mg and 500 mg vials on back order and the company expects a release date of late-May 2018 for the 200 mg vials and early-May 2018 for the 500 mg vials.
- West-Ward has leucovorin 350 mg vials on allocation. The 50 mg and 200 mg vials are on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=35>

### Labetalol Injection

**April 23, 2018**

#### Reason for the Shortage

- Akorn has labetalol injection available.[1]
- Alvogen has labetalol injection available.[2]
- Pfizer has labetalol injection on shortage due to manufacturing delays.[3]
- West-Ward has labetalol injection available.[4]

#### Estimated Resupply Dates

- Pfizer has labetalol 5 mg/mL 4 mL syringes on back order and the company cannot estimate a release date.[3]

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=286>

### Famotidine Injection

**April 23, 2018**

#### Reason for the Shortage

- Ben Venue stopped production in its plant in Bedford, Ohio and closed in July 2014.[1]
- West-Ward has famotidine vials available.[2]
- Pfizer launched famotidine injections in March 2012.[3]
- Mylan Institutional acquired famotidine injections from Pfizer on December 6, 2013.[4]
- Fresenius Kabi did not provide a reason for the shortage.[5]
- Baxter has famotidine premixed bags available.[6]

#### Estimated Resupply Dates

- Fresenius Kabi has famotidine 2 mL, 4 mL, and 20 mL vials on back order and the company estimates a release date of early-May 2018 for the 2 mL vials, late-May 2018 for the 4 mL vials, and mid-May 2018 for the 20 mL vials.[5]
- Mylan Institutional has famotidine 2 mL and 20 mL vials on back order and the company estimates a release date of early-May 2018 for the 2 mL vials and early-July 2018 for the 20 mL vials.[4]
- West-Ward has famotidine 4 mL and 20 mL vials on back order and the company estimates a release date of May 2018. The 2 mL vials are on allocation.[2]

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=166>

**Etoposide****April 23, 2018**

## Reason for the Shortage

- Accord has etoposide on back order due to increased demand.
- Fresenius Kabi has etoposide on back order due to increased demand.
- Teva did not provide a reason for the current shortage.
- Etoposide phosphate powder for injection (Etopophos) is unaffected by this shortage.

## Estimated Resupply Dates

- Accord has etoposide 50 mL vials on intermittent back order and the company is releasing product as it becomes available. The 5 mL and 25 mL vials are on back order and the company estimates a release date of late-April 2018.
- Fresenius Kabi has etoposide 20 mg/mL 5 mL, 25 mL, and 50 mL vials on back order and the company estimates a release date of early-June 2018 for the 5 mL and 25 mL vials, and late-May 2018 for the 50 mL vials. Check wholesalers for inventory.
- Teva has Toposar 20 mg/mL 5 mL, 25 mL, and 50 mL vials on allocation.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=369>

**Diazepam Injection****April 23, 2018**

## Reason for the Shortage

- Pfizer has diazepam on shortage due manufacturing delays.

## Estimated Resupply Dates

- Pfizer has diazepam 5 mg/mL 2 mL Carpuject syringes on back order and the company cannot estimate a release date

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=330>

**Calcium Gluconate Injection****April 23, 2018**

## Reason for the Shortage

- American Regent has calcium gluconate on shortage due to manufacturing delays.
- Fresenius Kabi has calcium gluconate available with alternating short-dating due to manufacturing process of the vials.

## Estimated Resupply Dates

- American Regent has calcium gluconate 100 mg/mL 50 mL and 100 mL vials on back order and the company cannot estimate a release date.
- Fresenius Kabi has calcium gluconate 100 mg/mL 10 mL, 50 mL, and 100 mL vials on back order and the company estimates a release date of early-May 2018.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=150>

**Aminophylline Injection****April 23, 2018**

## Reason for the Shortage

- Pfizer has aminophylline injection on shortage due to manufacturing delays.

## Estimated Resupply Dates

- Pfizer has aminophylline 25 mg/mL 10 mL and 20 mL vials on back order and the company estimates a release date of June 2018.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=407>

**0.9% Sodium Chloride 10 MI, 20 MI, and 50 MI Preservative Free Vials and Syringes****April 23, 2018**

## Reason for the Shortage

- Fresenius Kabi did not provide a reason for the shortage.
- Pfizer has 0.9% sodium chloride preservative-free vials on shortage due to manufacturing delays.

## Estimated Resupply Dates

- Fresenius Kabi has 0.9% sodium chloride preservative free 10 mL and 20 mL vials on back order and the company estimates a release date of late-April 2018 for the 10 mL vials and mid- to late-June 2018 for the 20 mL vials.
- Pfizer has 0.9% sodium chloride preservative free 10 mL LifeShield syringes on back order and the company estimates a release date of June 2018. The 10 mL, 20 mL, and 50 mL vials are on back order and the company estimates a release date of April 2018 for the 10 mL vials, June 2018 for the 20 mL vials, and May 2018 for the 50 mL vials.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=332>

\*Please refer to ASHP website for more information at:

<http://www.ashp.org/menu/DrugShortages/CurrentShortages/>

**14.6% Sodium Chloride Concentrated Solution For Injection****April 19, 2018**

## Reason for the Shortage

- Pfizer has 14.6% sodium chloride concentrated solution for injection on shortage due to manufacturing delays.

## Estimated Resupply Dates

- Pfizer has 14.6% sodium chloride concentrated solution for injection 20 mL vials on back order and the company estimates a release date of June 2018. The 40 mL vials are available for direct orders only. They have an expiration date of May 2018.
- Fresenius Kabi has 14.6% sodium chloride concentrated solution for injection 40 mL vials available with an expiration date of < 3 months.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=416>



**3% and 5% Sodium Chloride Large Volume Injection****April 19, 2018**

## Reason for the Shortage

- Baxter has 3% and 5% sodium chloride large volume for injection on shortage due to manufacturing delays. They are concentrating on other sizes.
- BBraun did not provide a reason for the shortage.

## Estimated Resupply Dates

- Baxter has 3% sodium chloride 500 mL bags on long-term back order and the company cannot estimate a release date. The 5% sodium chloride 500 mL bags are available in limited supply.
- BBraun has 3% sodium chloride 500 mL bags and 5% sodium chloride 500 mL bags on allocation to current customers.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=415>

**Butorphanol Tartrate Injection****April 19, 2018**

## Reason for the Shortage

- Pfizer has butorphanol injection on shortage due to manufacturing delays.

## Estimated Resupply Dates

- Pfizer has butorphanol 1 mg/mL 1 mL vials and 2 mg/mL 1 mL vials on back order and the company estimates a release date of mid-May 2018.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=414>

**Carbidopa and Levodopa Extended-Release Tablets****April 19, 2018**

## Reason for the Shortage

- Accord has discontinued carbidopa and levodopa 25 mg/100 mg extended-release tablets. The 50 mg/200 mg tablets are on shortage due to problems obtaining active ingredient.
- Sun Pharma had carbidopa and levodopa extended-release tablets on shortage due to increased demand.
- Merck had Sinemet CR on shortage due to increased demand.
- Mylan could not provide a reason for the shortage.

## Estimated Resupply Dates

- Accord has carbidopa and levodopa 50 mg/200 mg extended-release tablets on back order and the company estimates a release date of May 2018.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=349>

**Ceftriaxone Sodium Injection****April 19, 2018**

## Reason for the Shortage

- Apotex states the reason for the shortage is manufacturing delays. Apotex launched several products with new NDC numbers in June 2017.
- Fresenius Kabi stated the reason for the shortage was increased demand.
- Pfizer has some ceftriaxone presentations available and did not provide a reason for the back order of some presentations.
- Sagent states the reason for the shortage is manufacturing delay.
- Sandoz has most ceftriaxone presentations available.
- West-Ward states the reason for the shortage is manufacturing delay.
- Wockhardt relaunched their ceftriaxone presentations in October 2017.

## Estimated Resupply Dates

- Apotex has ceftriaxone presentations on intermittent back order and the company is releasing supplies as they become available.
- Lupin has all ceftriaxone presentations on allocation.
- Pfizer has ceftriaxone 250 mg vials, 1 gram ADD-Vantage vials, 2 gram vials, and 2 gram ADD-Vantage vials on allocation.
- Sagent has ceftriaxone 2 gram vials on back order and the company estimates a release date in May 2018.
- Wockhardt has all ceftriaxone presentations on back order and the company cannot estimate a release date.
- West-Ward has ceftriaxone 500 mg vials on back order and the company cannot estimate a release date. The 2 gram vials are also on back order and the company estimates a release date in mid-May to mid-June 2018.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=86>

**Etoposide****April 19, 2018**

## Reason for the Shortage

- Accord has etoposide on back order due to increased demand.
- Fresenius Kabi has etoposide on back order due to increased demand.
- Teva did not provide a reason for the current shortage.
- Etoposide phosphate powder for injection (Etopophos) is unaffected by this shortage.

## Estimated Resupply Dates

- Accord has etoposide 50 mL vials on intermittent back order and the company is releasing product as it becomes available. The 5 mL and 25 mL vials are on back order and the company estimates a release date of late-April 2018.
- Fresenius Kabi has etoposide 20 mg/mL 5 mL, 25 mL, and 50 mL vials on back order and the company estimates a release date of mid-May 2018 for the 5 mL and 25 mL vials, and late-May 2018 for the 50 mL vials. Check wholesalers for inventory.
- Teva has Toposar 20 mg/mL 5 mL, 25 mL, and 50 mL vials on allocation.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=369>

### **Oxacillin Sodium Injection**

**April 19, 2018**

#### Reason for the Shortage

- AuroMedics did not provide a reason for the shortage.
- Baxter has oxacillin on shortage due to manufacturing delays.
- Sagent has oxacillin on shortage due to manufacturing delays.

#### Estimated Resupply Dates

- AuroMedics has all oxacillin presentations on long-term back order and the company cannot estimate a release date.
- Baxter has oxacillin 1gram/50 mL and 2 gram/50 mL premixes available in limited supply.
- Sagent has oxacillin 10 gram bulk vials on allocation.
- Wockhardt estimates a launch date in early-May 2018 for oxacillin 10 grams vials.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=377>

### **Amino Acid Products With Electrolytes and Calcium**

**April 18, 2018**

#### Reason for the Shortage

- Baxter has all Clinimix E with electrolytes plus calcium presentations on allocation due to delays because of the hurricane in Puerto Rico.
- To help alleviate the critical drug shortages resulting from the aftermath of Hurricane Maria, FDA has allowed Baxter to temporarily import the following amino acid products: Clinimix N9G15E, Clinimix N9G20E, and Clinimix N14G30E solutions for infusion. Additional information can be found in the Dear Healthcare Professional Letter.

<https://www.fda.gov/downloads/Drugs/DrugSafety/DrugShortages/UCM584414.pdf>

#### Estimated Resupply Dates

- Baxter has all amino acid products with electrolytes plus calcium on allocation.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=354>

### **Amino Acids In Dextrose**

**April 18, 2018**

#### Reason for the Shortage

- Baxter has all Clinimix presentations on allocation due to delays because of the hurricane in Puerto Rico.

#### Estimated Resupply Dates

- Baxter has Clinimix 4.25%/20% in 2000 mL bags, 4.25%/25% in 2000 mL, and 5%/15% in 1000 mL bags on back order and the company cannot estimate a release date. All other presentations are on allocation.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=355>

**Cefepime Injection****April 18, 2018**

## Reason for the Shortage

- Apotex did not provide a reason for the shortage.
- Baxter had cefepime on shortage due to increased demand.
- BBraun has cefepime on shortage due to increased demand.
- Fresenius Kabi had cefepime injection on shortage due to manufacturing delays.
- Pfizer has Maxipime on shortage due to manufacturing delays.
- Sagent had cefepime injection on shortage due to manufacturing delays.
- Sandoz discontinued cefepime injection in early-2016.
- WG Critical Care had cefepime injection on shortage due to increased demand.

## Estimated Resupply Dates

- Apotex has cefepime presentations on back order and the company estimates a release date in early- to mid-May 2018.
- BBraun has cefepime 1 gram and 2 gram premixed bags on allocation to current customers.
- Pfizer has Maxipime 1 gram vials, 2 gram vials, and 1 gram ADD-Vantage vials on back order and the company estimates a release date of mid-May 2018.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=59>

**Cefoxitin Sodium Injection****April 18, 2018**

## Reason for the Shortage

- Fresenius Kabi and West-Ward did not provide a reason for the shortage.
- Sagent had cefoxitin on shortage due to manufacturing delays.
- BBraun has cefoxitin on allocation due to increased demand.
- WG Critical Care did not provide a reason for the back order.
- Apotex did not provide a reason for the shortage.

## Estimated Resupply Dates

- West-Ward has cefoxitin 1 gram, 2 gram, and 10 gram vials on back order and the company estimates a release date of early to mid-May 2018 for the 1 gram vials and cannot estimate a release date for the 2 gram and 10 gram vials.
- BBraun has cefoxitin 1 gram and 2 gram vials on allocation.
- WG Critical Care has cefoxitin 1 gram vials on back order and the company estimates a release date of early to mid-May 2018.
- Apotex has temporarily discontinued cefoxitin 1 gram, 2 gram, and 10 gram vials and the company cannot estimate when product will be available again.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=271>

### Doxorubicin Injection

April 18, 2018

#### Reason for the Shortage

- West-Ward has Adriamycin available.[1]
- Teva has doxorubicin solution for injection on allocation due to increased demand.[2,3]
- Fresenius Kabi has doxorubicin solution for injection available.[4]
- Caraco has discontinued doxorubicin solution for injection 25 mL and 100 mL vials.[5]
- Pfizer has doxorubicin on shortage due to manufacturing delays.[6]
- Sagent discontinued doxorubicin solution for injection in late-2017.[7]
- Mylan Institutional has doxorubicin lyophilized powder for injection available.[8]
- Athenex has doxorubicin available.[9]
- FDA was allowing temporary importation of doxorubicin lyophilized powder for injection 50 mg vials. These vials were manufactured for Hospira UK Limited. The labeling as well as bar coding for the imported product is different from the US version. FDA has the Dear Healthcare Professional Letter linked on their website. The letter includes a link to both the US and United Kingdom package inserts to help explain the differences in labeling and packaging. The link to the letter is <http://www.fda.gov/downloads/Drugs/DrugSafety/DrugShortages/UCM507498.pdf>. Ordering can be done directly with Hospira Customer Care at 877-946-7747. [10,11].

#### Estimated Resupply Dates

- Mylan Institutional has doxorubicin lyophilized powder 10 mg vials on back order and the company cannot estimate a release date. The 50 mg vials are available with an expiration date of January 2019.[8]
- Pfizer has doxorubicin 2 mg/mL 5 mL, 75 mL, and 100 mL vials on allocation.[6]
- Teva has doxorubicin 2 mg/mL 25 mL vials (NDC 45963-0733-68) on back order and the company will allocate these as they become available. The 2 mg/mL 100 mL vials (NDC 45963-0733-60) are on allocation.[2].

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=108>

### Fluorouracil Injection

April 18, 2018

#### Reason for the Shortage

- Accord did not provide a reason for the shortage.
- Fresenius Kabi did not provide a reason for the shortage.
- Teva has fluorouracil injection on allocation due to increased demand.

#### Estimated Resupply Dates

- Accord had fluorouracil 50 mg/mL 10 mL, 20 mL, 50 mL, and 100 mL vials on back order and the company estimates a release date of early-May 2018 for the 10 mL and 50 mL vials and late-April 2018 for the 20 mL and 100 mL vials.
- Fresenius Kabi has fluorouracil 50 mg/mL 20 mL, 50 mL, and 100 mL vials on back order and the company estimates a release date of mid-April 2018 for the 20 mL and 100 mL vials and mid-May 2018 for the 50 mL vials.

- Teva has Adriel 10 mL, 50 mL, and 100 mL vials on allocation..
- <https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=401>

### Haloperidol Lactate Injection

**April 18, 2018**

#### Reason for the Shortage

- Mylan Institutional has haloperidol lactate injection available.
- Patriot Pharmaceuticals has haloperidol lactate available.
- Sagent has discontinued haloperidol 5 mg/mL 10 mL vials. The company plans to relaunch the product in May 2018.
- Teva is not currently marketing haloperidol lactate.
- West-Ward is not actively marketing haloperidol lactate at this time.
- Janssen has Haldol injection available.

#### Estimated Resupply Dates

- Sagent has discontinued haloperidol lactate 5 mg/mL 10 mL vials. The company plans to relaunch the product in May 2018.
- Fresenius Kabi has haloperidol lactate 5 mg/mL 10 mL vials available but with short dating of less than or equal to 6 months.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=30>

### Hepatitis B Vaccine (Recombinant)

**April 18, 2018**

#### Reason for the Shortage

- Merck has Recombivax HB on shortage due to increase in global demand.
- GlaxoSmithKline discontinued Engerix B pediatric vials in October 2017.

#### Estimated Resupply Dates

- GlaxoSmithKline has Engerix B presentations available in limited supply.
- Merck has Recombivax HB adult formulation vials and syringes on back order and the company estimates this will continue through 2018.
- Merck has Recombivax HB pediatric/adolescent formulation syringes and pediatric/adolescent vials on back order and the company estimates this will continue through 2018. Merck's limited supply is being allocated to the CDC to ensure use is in accordance with their clinical guidance.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=320>

### Ketamine Injection

**April 18, 2018**

#### Reason for the Shortage

- Mylan Institutional did not provide a reason for the shortage.
- Par has Ketalar on shortage due to increased demand.
- Pfizer has ketamine on shortage due to manufacturing delays.
- West-Ward did not provide a reason for the shortage.

#### Estimated Resupply Dates

- Mylan Institutional has ketamine 10 mg/mL 20 mL vials on back order and the company estimates a release date of mid-April 2018. The 50 mg/mL 10 mL vials are on back order and the company estimates a release date of late-April 2018. The 100 mg/mL 5 mL vials are on back order and the company estimates a release date of late-April 2018.
- Pfizer has ketamine 50 mg/mL 10 mL vials and 100 mg/mL 5 mL vials on back order and the company estimates a release date of March 2019.
- West-Ward has ketamine 50 mg/mL 10 mL vials and 100 mg/mL 5 mL vials on allocation.
- Par has Ketalar 10 mg/mL 20 mL vials, 50 mg/mL 10 mL vials, and 100 mg/mL 5 mL vials on intermittent back order with regular releases.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=391>

#### Leuprolide Acetate 14-Day Kit

**April 18, 2018**

#### Reason for the Shortage

- Sun Pharma did not provide a reason for the shortage.
- Sandoz states the reason for the shortage was increased demand.
- Teva states the shortage is due to manufacturing delays.

#### Estimated Resupply Dates

- Sandoz has leuprolide acetate injection on back order and the company estimates a release date in early-May 2018.
- Teva has leuprolide acetate injection on long-term back order and the company cannot estimate a release date.
- Sun Pharma has leuprolide acetate injection on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=81>

#### Sincalide Injection

**April 18, 2018**

#### Reason for the Shortage

- Bracco Diagnostics has Kinevac injection on shortage due to a supply disruption.
- There are no approved alternatives to Kinevac for the labeled indications.

#### Estimated Resupply Dates

- Bracco has Kinevac on allocation..

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=277>

#### Sterile Water For Injection Large Volume Bags

**April 18, 2018**

#### Reason for the Shortage

- Baxter has sterile water for injection on shortage due to manufacturing delays.
- BBraun did not provide a reason for the shortage.
- ICU Medical has sterile water for injection on shortage due to increased demand.

**Estimated Resupply Dates**

- Baxter has sterile water for injection presentations on allocation.
- BBraun has all sterile water for injection bags on allocation to current customers.
- ICU Medical has sterile water for injection 2000 mL bags available in limited supply.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=368>

**Thiamine Injection****April 18, 2018****Reason for the Shortage**

- Fresenius Kabi had thiamine injection on shortage due to short-term manufacturing delays.
- Mylan Institutional did not provide a reason for the shortage.

**Estimated Resupply Dates**

- Mylan Institutional has thiamine 100 mg/mL 2 mL vials on back order and the company estimates a release date of early-May 2018.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=387>

**Fomepizole Injection****April 17, 2018****Reason for the Shortage**

- Mylan Institutional did not provide a reason for the shortage.
- X-Gen has fomepizole on shortage due to increased demand.

**Estimated Resupply Dates**

- Mylan Institutional has fomepizole 1 gram/mL 1.5 mL vials on back order and the company estimates a release date of mid-April 2018.
- X-Gen has fomepizole 1 gram/mL 1.5 mL vials on back order and the company estimates a release date of mid-April 2018.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=394>

**Metronidazole Hydrochloride Injection****April 17, 2018****Reason for the Shortage**

- Pfizer has metronidazole injection on shortage due to manufacturing delay.
- BBraun did not provide a reason for the metronidazole injection shortage.

**Estimated Resupply Dates**

- BBraun has metronidazole 100 mL bags on back order and the company cannot estimate a release date.
- Pfizer has metronidazole 100 mL bags in 24 count and 80 count on back order and the company estimates a release date of late-April 2018 for the 24 count presentations and early-May 2018 for the 80 count presentations..



<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=316>

### **Mupirocin Calcium 2% Cream**

**April 17, 2018**

#### Reason for the Shortage

- GlaxoSmithKline is looking for an alternative supply source.
- Prasco discontinued mupirocin calcium 2% cream in February 2016.

#### Estimated Resupply Dates

- GlaxoSmithKline has Bactroban 2% cream in 15 gram and 30 gram sizes on long-term back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=162>

### **Ropivacaine Injection**

**April 17, 2018**

#### Reason for the Shortage

- Akorn has ropivacaine on shortage due to increased demand.
- AuroMedics did not provide a reason for the shortage.
- Fresenius Kabi has Naropin on shortage due to increased demand and manufacturing delays.
- Pfizer has ropivacaine on shortage due to manufacturing delays.

#### Estimated Resupply Dates

- Akorn has ropivacaine 2 mg/mL 30 mL vials on back order and the company cannot estimate a release date.
- AuroMedics has ropivacaine 2 mg/mL 20 mL vials and 100 mL bottles, 5 mg/mL 20 mL and 30 mL vials, 7.5 mg/mL 20 mL vials, and 10 mg/mL 10 mL and 20 mL vials on intermittent back order and the company is releasing product as it becomes available.
- Pfizer has ropivacaine 2 mg/mL 10 mL and 20 mL vials on back order and the company estimates a release date of September 2018 for the 10 mL vials and May 2018 for the 20 mL vials. The 5 mg/mL 30 mL vials are on back order and the company estimates a release date of May 2018. The 7.5 mg/mL 20 mL vials are on back order and the company estimates a release date of July 2018. The 10 mg/mL 10 mL and 20 mL vials are on back order and the company estimates a release date of September 2018 for the 10 mL vials and May 2018 for the 20 mL vials.
- Fresenius Kabi has Naropin 2 mg/mL 100 mL and 200 mL bottles on back order and the company estimates a release date of late-April 2018 for the 100 mL bottles and early-May 2018 for the 200 mL bottles. The 2 mg/mL 100 mL and 200 mL premixed bags are on back order and the company estimates a release date of mid-May 2018. The 5 mg/mL 20 mL vials are on back order and the company estimates a release date of early-May 2018. The 5 mg/mL 20 mL and 30 mL Steripak ampules are on back order and the company estimates a release date of mid-May 2018 for the 20 mL ampules and mid-June 2018 for the 30 mL ampules. The 7.5 mg/mL 20 mL vials are on back order and the company estimates a release date of late-April 2018. The 7.5 mg/mL 20 mL Steripak ampules are on back order and the company estimates a release date of mid-May 2018. The 10 mg/mL 10 mL and 20 mL vials are on back order and the company

estimates a release date of early-May 2018 for the 10 mL vials and early-May 2018 for the 20 mL vials. The 10 mg/mL 10 mL and 20 mL Steripak ampules are on back order and the company estimates a release date of mid-May 2018 for the 10 mL ampules and late-May 2018 for the 20 mL ampules. Check wholesalers for inventory.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=384>

### Sodium Bicarbonate Injection

**April 17, 2018**

#### Reason for the Shortage

- Amphastar has sodium bicarbonate injection on shortage due to increased demand.[1]
- Pfizer has sodium bicarbonate injection on shortage due to manufacturing delays.[2]
- Fresenius Kabi has reintroduced sodium bicarbonate injection in response to the shortage.[3].

#### Estimated Resupply Dates

- Amphastar has 8.4 % sodium bicarbonate 50 mL syringes on allocation.[1]
- Pfizer has 8.4% sodium bicarbonate 10 mL syringes on back order and the company estimates a release date of late-June 2018. The 4.2% sodium bicarbonate 10 mL LifeShield syringes are available in limited supply.[2].

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=293>

### 0.9% Sodium Chloride Small Volume Bags (<150 ML)

**April 16, 2018**

#### Reason for the Shortage

- Baxter has 0.9% sodium chloride small volume bags on shortage due to manufacturing delays.
- BBraun has 0.9% sodium chloride small volume bags on shortage due to increased demand.
- ICU Medical has 0.9% sodium chloride small volume bags on shortage due to increased demand.

#### Estimated Resupply Dates

- Baxter has all 0.9% sodium chloride small volume bags on allocation.
- BBraun has all 0.9% sodium chloride small volume bags on allocation to current customers only.
- Pfizer has 0.9% sodium chloride 50 mL preservative-free vials, 50 mL Add-Vantage bags, and 100 mL Add-Vantage bags on allocation.
- ICU Medical has the 0.9% sodium chloride 50 mL VisIV bags, 50 mL bags, 100 mL VisIV bags, and 100 mL bags (80 count) on intermittent back order and the company is releasing supplies as they become available. The 50 mL preservative-free bags are on back order and the company estimates a release date in early-June 2018. The 100 mL bags (48 count) are on back order and the company estimates a release date in mid-May 2018.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=352>

### Abciximab Injection

**April 16, 2018**

**Reason for the Shortage**

- Janssen has Reopro on shortage due to a production interruption at their third party manufacturing site. The contract manufacturer cannot guarantee supply continuity in 2018 and beyond.
- There are no other suppliers of abciximab.

**Estimated Resupply Dates**

- Janssen has Reopro on long-term back order and the company cannot estimate a release date.
- <https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=413>

**Acetylcysteine Oral and Inhalation Solution****April 16, 2018****Reason for the Shortage**

- American Regent has acetylcysteine oral and inhalation solution on shortage due to manufacturing delays.
- Fresenius Kabi has acetylcysteine oral and inhalation solution available.
- Pfizer has acetylcysteine oral and inhalation solution on shortage due to manufacturing delays.
- Roxane Labs discontinued acetylcysteine oral and inhalation solution in April 2014.
- Arbor has Cetylev effervescent tablets available. These are for oral use only.

**Estimated Resupply Dates**

- American Regent has acetylcysteine solution 100 mg/mL 10 mL and 200 mg/mL 10 mL and 30 mL vials on back order and the company cannot estimate a release date.
- Fresenius Kabi has acetylcysteine solution 200 mg/mL 4 mL and 10 mL vials on back order and the company estimates a release date of mid-April 2018. The 100 mg/mL 4 mL and 10 mL vials are on back order and the company estimates a release date of mid-April 2018. The 100 mg/mL 30 mL vials are on back order and the company estimates a release date of mid-May 2018.
- Pfizer has acetylcysteine solution 100 mg/mL 30 mL vials and 200 mg/mL 30 mL vials on back order and the company estimates a release date of May 2018.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=43>

**Atropine Sulfate Injection****April 16, 2018****Reason for the Shortage**

- American Regent had atropine injection on shortage due to market demand.
- Pfizer has atropine injection on shortage due to manufacturing delays.
- West-Ward did not provide a reason for the shortage.

**Estimated Resupply Dates**

- American Regent has 1 mg/mL 1 mL vials available in limited quantities. The 0.4 mg/mL 1 mL vials are on back order and the company cannot estimate a release date.
- Pfizer has atropine 0.1 mg/mL 10 mL Ansyr syringes available on back order and the company estimates a release date of late-June 2018. The 0.1 mg/mL 5 mL LifeShield syringes are on back order and the company estimates a release date of early-May 2018. The 0.1 mg/mL 10 mL

LifeShield syringes are on back order and the company estimates a release date of early-May 2018.

- West-Ward has atropine 0.4 mg/mL 20 mL vials on allocation.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=46>

### **Doxycycline Hyclate Injection**

**April 16, 2018**

Reason for the Shortage

- Mylan Institutional temporarily discontinued doxycycline 100 mg vials in March 2016.
- Fresenius Kabi had doxycycline injection on shortage due to increased demand.

Estimated Resupply Dates

- Fresenius Kabi has doxycycline 100 mg vials available.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=356>

### **Penicillamine**

**April 16, 2018**

Reason for the Shortage

- Mylan did not provide a reason for the shortage.

Estimated Resupply Dates

- Mylan has Depen tablets available with an expiration date of September 2018.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=379>

### **Trace Elements Injection**

**April 16, 2018**

Reason for the Shortage

American Regent did not provide a reason for the shortage.

Estimated Resupply Dates

- American Regent has trace elements-4 pediatric vials on back order and the company cannot estimate a release date. The Multitrace-4 Concentrate 1 mL vials, Multitrace-4 Pediatric 3 mL vials, Multitrace-5 regular 10 mL vials, and Multitrace-5 Concentrate 10 mL vials are available in limited supply.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=319>

### **Atropine Sulfate Injection**

**April 16, 2018**

Reason for the Shortage

- Pfizer has vecuronium on shortage due to manufacturing delays.[1-2]
- Teva has vecuronium on allocation due to increased demand.[3]
- Pfizer sold vecuronium injection to Mylan Institutional in December 2013.[4-5]

- Ben Venue has stopped production in its plant in Bedford, Ohio and closed in 2014.[6]
- Sun Pharma has vecuronium available.[7]
- Sagent is not marketing vecuronium 10 mg and 20 mg vials.[8]
- Fresenius Kabi has vecuronium on shortage due to manufacturing delays.[9].

#### Estimated Resupply Dates

- Fresenius Kabi has vecuronium 10 mg vials on back order and the company estimates a release date of early-May 2018.[9]
- Mylan Institutional has vecuronium 20 mg vials on back order with an estimated release date of early-May 2018. The 10 mg vials are available with an expiration date of November 2018.[5]
- Pfizer has vecuronium 10 mg and 20 mg vials on back order and the company estimates a release date of 2019.[2]
- Teva has vecuronium 10 mg vials on allocation.[3].

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=167>

### Vincristine Sulfate Injection

**April 16, 2018**

#### Reason for the Shortage

- Pfizer has vincristine on shortage due to manufacturing delays.
- Teva has Vincasar on shortage due to increased demand.

#### Estimated Resupply Dates

- Pfizer has vincristine 1 mg/mL 1 mL vials on back order and the company estimates a release date of June 2018.
- Teva has Vincasar 1 mg/mL 1 mL and 2 mL vials on allocation. Check wholesaler for availability.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=382>

### Tobramycin Sulfate Injection

**April 13, 2018**

#### Reason for the Shortage

- Akorn has tobramycin injection on shortage due to manufacturing delays.
- Pfizer did not provide a reason for the shortage.

#### Estimated Resupply Dates

- Akorn has tobramycin 40 mg/mL 2 mL and 30 mL vials available with an expiration date of <11 months.
- Mylan Institutional has tobramycin 40 mg/mL 2 mL vials on back order and the company estimates a release date of early-May 2018.
- Teva has temporarily discontinued tobramycin 40 mg/mL 2 mL vials.
- Fresenius Kabi has tobramycin 1.2 gram powder for injection on back order and the company estimates a release date of late-May 2018.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=164>

**Sodium Phosphate Injection****April 13, 2018**

## Reason for the Shortage

- American Regent has sodium phosphate injection on shortage due to manufacturing delay.[1]
- Fresenius Kabi states the reason for the shortage is increased demand.[2]
- Pfizer has sodium phosphate injection on shortage due to manufacturing delay.[3]

## Estimated Resupply Dates

- American Regent has sodium phosphate 3 mmol/mL 5 mL, 15 mL, and 50 mL vials on back order and the company cannot estimate a release date.[1]
- Pfizer has sodium phosphate 3 mmol/mL 15 mL vials on back order and the company estimates a release date of March 2019.[3]

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=227>

**Prothrombin Complex Concentrate (Kcentra)****April 13, 2018**

## Reason for the Shortage

- CSL Behring had short-term delays in product releases.

## Estimated Resupply Dates

- CSL Behring has Kcentra on intermittent back order with regular releases.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=404>

**Potassium Phosphate Injection****April 13, 2018**

## Reason for the Shortage

- American Regent has not had potassium phosphate injection available since 2012. It is unclear if and when product will return to market.
- Fresenius Kabi had potassium phosphate injection on shortage due to increased demand.
- Pfizer has potassium phosphate injection on shortage due to manufacturing delays.

## Estimated Resupply Dates

- All marketed presentations are available.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=305>

**Metoclopramide Injection****April 13, 2018**

## Reason for the Shortage

- Pfizer has metoclopramide injection on shortage due to manufacturing delays.
- Teva has metoclopramide injection on shortage due to increased demand.
- Fresenius Kabi has metoclopramide injection on shortage due to increased demand.

## Estimated Resupply Dates

- Pfizer has metoclopramide 5 mg/mL 2 mL vials available in limited supply.

- Teva has metoclopramide 5 mg/mL 2 mL vials on allocation.
- Fresenius Kabi has metoclopramide 5 mg/mL 2 mL syringes on back order and the company estimates a release date of mid- to late-June 2018.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=338>

### Magnesium Sulfate Injection

**April 13, 2018**

#### Reason for the Shortage

- American Regent has had magnesium sulfate unavailable since late 2012.
- Fresenius Kabi has magnesium sulfate injection on shortage due to increased demand for the product.
- Pfizer has magnesium sulfate injection on shortage due to manufacturing delays.
- X-Gen did not provide a reason for the shortage.

#### Estimated Resupply Dates

- Fresenius Kabi has magnesium sulfate 500 mg/mL 20 mL and 50 mL vials on back order and the company estimates a release date of late-May 2018 for the 20 mL vials and early-May 2018 for the 50 mL vials. The 500 mg/mL 2 mL and 10 mL vials are on back order and the company cannot estimate a release date. The 40 mg/mL 500 mL premixed bags are on back order and the company estimates a release date of late-June 2018. The 40 mg/mL 1,000 mL premixed bags are available with expiration dates of <2 months.
- Pfizer has magnesium sulfate 500 mg/mL 20 mL vials on back order and the company estimates a release date of June 2018. The 500 mg/mL 10 mL syringes are on back order and the company estimates a release date of September 2018. The magnesium sulfate 40 mg/mL 50 mL and 100 mL bags are on back order and the company estimates a release date of May 2018 for the 50 mL bags and late-May 2018 for the 100 mL bags. The 40 mg/mL 500 mL and 1,000 mL bags are available in limited supply. The 80 mg/mL 50 mL bags are available in limited supply.
- X-Gen has 500 mg/mL 10 mL vials on long-term back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=21>

### Iron Dextran Injection

**April 13, 2018**

#### Reason for the Shortage

- Allergan has INFeD on shortage due to manufacturing delays.
- American Regent discontinued Dexferrum injection in 2014.

#### Estimated Resupply Dates

- Allergan has INFeD 50 mg/mL 2 mL vials on back order and the company estimates a release date of late-April 2018.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=408>

### Deferoxamine Injection

**April 13, 2018**

#### Reason for the Shortage

- Fresenius Kabi has deferoxamine on shortage due to increased demand.
- Pfizer has deferoxamine on shortage due to manufacturing delays.
- Novartis has Desferal on shortage due to increased demand.

#### Estimated Resupply Dates

- Fresenius Kabi has deferoxamine 500 mg and 2 gram vials on back order and the company estimates a release date of late-April 2018 for the 500 mg vials and late-May 2018 for the 2 gram vials. Check wholesalers for inventory.
- Pfizer has deferoxamine 500 mg and 2 gram vials on back order and the company estimates a release date of March 2019. Pfizer has a limited supply of short-dated 2 gram vials.
- Novartis has Desferal 500 mg vials available in limited supply.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=393>

### 23.4% Sodium Chloride Injection

**April 13, 2018**

#### Reason for the Shortage

- Fresenius Kabi has 23.4% sodium chloride injection on shortage due to increased demand.
- Pfizer has 23.4% sodium chloride injection on shortage due to increased demand.

#### Estimated Resupply Dates

- Fresenius Kabi has 23.4% sodium chloride 30 mL, 100 mL, and 200 mL vials on back order and the company estimates a release date of late-May 2018 for the 30 mL, early-June for the 100 mL vials, and early-May 2018 for the 200 mL vials.
- Pfizer has 23.4% sodium chloride 200 mL vials on back order and the company estimates a release date of July 2018.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=336>

### 0.9% Sodium Chloride Large Volume Bags

**April 13, 2018**

#### Reason for the Shortage

- Baxter discontinued 0.9% sodium chloride 250 mL and 500 mL AVIVA bags. The Viaflex bags and Viaflo bags are on allocation.[1]
- BBraun did not provide a reason for the shortage.[2]
- ICU Medical cited increased demand as the reason for the shortage.[3]
- Fresenius Kabi is no longer importing product.[8]
- Baxter has received FDA approval for 0.9% sodium chloride in Viaflo containers manufactured in an FDA-approved facility in Spain. Additional information about this product is available at: [http://www.baxter.com/information/saline\\_supply.html](http://www.baxter.com/information/saline_supply.html).

#### Estimated Resupply Dates

- Baxter has all 0.9% sodium chloride presentations on allocation.[1]



- BBraun has 0.9% sodium chloride 250 mL, 500 mL, and 1,000 mL PVC/DEHP-free bags on allocation to current customers.[2]
- ICU Medical has 0.9% sodium chloride 150 mL bags on intermittent back order and the company is releasing supplies as they become available.[3]

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=76>

### Vancomycin Hydrochloride Injection

**April 12, 2018**

#### Reason for the Shortage

- Athenex has vancomycin injection available.[1]
- Pfizer has vancomycin vials on back order due to manufacturing delays.[2]
- Fresenius Kabi has vancomycin injection on shortage due to increased demand.[3]
- Mylan Institutional has vancomycin injection available.[4]
- Sagent has vancomycin injection on shortage due to manufacturing delays and increased demand.[7]
- Baxter has vancomycin injection available.[5]
- Samson Medical Technologies has vancomycin injection available.[6]

#### Estimated Resupply Dates

- Fresenius Kabi has vancomycin 750 mg, 5 gram and 10 gram vials on intermittent back order with regular releases.
- Pfizer has vancomycin 500 mg vials, 750 mg, 1 gram vials, 5 gram vials, and 10 gram vials available in limited supply. The 500 mg ADD-Vantage vials, 750 mg ADD-Vantage vials, and 1 gram ADD-Vantage vials are on back order and the company estimates a release date of late-April 2018.[2]
- Sagent has vancomycin 5 gram vials on allocation. The 10 gram vials are on back order and the company estimates a release date of May 2018.[7]

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=25>

### Metoprolol Injection

**April 12, 2018**

#### Reason for the Shortage

- Alvogen has metoprolol injection available.[1]
- American Regent has had metoprolol injection on long-term back order for several years.[2]
- Athenex has metoprolol injection available.[3]
- Claris did not provide a reason for the shortage.[4]
- Fresenius Kabi has metoprolol injection on shortage due to increased demand.[5]
- Mylan Institutional acquired metoprolol injection from Sagent. They discontinued metoprolol injection in March 2018.[6]
- Pfizer has metoprolol injection on shortage due to manufacturing delays.[7]
- West-Ward has metoprolol injection available.[8]

#### Estimated Resupply Dates

- Baxter (formerly Claris) has metoprolol 1 mg/mL 5 mL vials on back order and the company cannot estimate a release date.[4]

- Fresenius Kabi has metoprolol 1 mg/mL 5 mL vials on back order and the company estimates a release date of mid-June 2018.[5]
- Pfizer has metoprolol 1 mg/mL 5 mL ampules on back order and the company estimates a release date of March 2019. The 1 mg/mL 5 mL Carpuject syringes are on back order and the company estimates a release date of June 2019.[7]
- West-Ward has metoprolol 1 mg/mL 5 mL vials on allocation.[8]

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=363>

### **Furosemide Injection**

**April 12, 2018**

#### Reason for the Shortage

- American Regent is not actively marketing furosemide injection.
- Claris has furosemide injection available.
- Fresenius Kabi has furosemide injection available.
- Heritage has furosemide injection available.
- Pfizer has furosemide injection on shortage due to manufacturing delays and increased demand.

#### Estimated Resupply Dates

- Fresenius Kabi has furosemide 10 mg/mL 10 mL vials on back order and the company cannot estimate a release date.
- Pfizer has furosemide 10 mg/mL 2 mL vials and 4 mL syringes on back order and the company estimates a release date of late-April 2018.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=323>

### **Ethiodized Oil**

**April 12, 2018**

#### Reason for the Shortage

- Guerbet states their Lipiodol product is in short supply due to manufacturing problems at Jubilant HollisterStier, the manufacturing site in Canada that supplies Lipiodol for Guerbet. The company estimates the shortage will last at least one year.[1-2]

#### Estimated Resupply Dates

- Guerbet is shipping supplies of Lipiodol Ultra-Fluide.[2] Lipiodol Ultra-Fluide is not FDA approved. In order to prevent a drug shortage, FDA is allowing Guerbet to import Lipiodol Ultra-Fluide, a product manufactured for Guerbet in France by Delpharm Tours.[2]
- Customers must order Lipiodol Ultra-Fluide directly from Guerbet by calling 1-877-729-6679. Lipiodol Ultra-Fluide is non-refundable and may not be resold.[2]

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=39>

### **Dexmedetomidine Hydrochloride In 0.9% Sodium Chloride Injection**

**April 12, 2018**

#### Reason for the Shortage

- Pfizer did not provide a reason for the shortage.

**Estimated Resupply Dates**

- Pfizer has Precedex 4 mcg/mL 50 mL premixed bottles on back order and the company estimates a release date of late-May 2018. Precedex 4 mcg/mL 20 mL vials and 100 mL premixed bottles are on allocation.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=398>

**Bupivacaine With Epinephrine Injection****April 12, 2018****Reason for the Shortage**

- Fresenius Kabi has bupivacaine and epinephrine on shortage due to increased demand and manufacturing delays.
- Pfizer has bupivacaine with epinephrine on shortage due to manufacturing delays.

**Estimated Resupply Dates**

- Fresenius Kabi has 0.25% Sensorcaine-MPF with epinephrine 10 mL vials on back order and the company cannot estimate a release date. The 0.25% Sensorcaine-MPF with epinephrine 30 mL vials are on back order and the company estimates a release date of mid-April 2018. The 0.25% Sensorcaine with epinephrine 50 mL vials are on back order and the company estimates a release date of mid-April 2018. The 0.5% Sensorcaine-MPF with epinephrine 10 mL vials are on back order and the company estimates a release date of mid-April 2018. The 0.5% Sensorcaine-MPF with epinephrine 30 mL vials are on back order and the company estimates a release date of mid-April 2018. The 0.5% Sensorcaine-MPF with epinephrine 30 mL sterile packs are on back order and the company cannot estimate a release date. The 0.5% Sensorcaine with epinephrine 50 mL vials are on back order and the company estimates a release date of mid-April 2018. The 0.75% Sensorcaine with epinephrine 30 mL vials are on back order and the company cannot estimate a release date.
- Pfizer has 0.25% bupivacaine with epinephrine 10 mL preservative-free vials on back order and the company estimates a release date of June 2018. The 0.25% bupivacaine with epinephrine 10 mL preservative-free vials are on back order and the company estimates a release date of mid-May 2018. The 0.25% bupivacaine with epinephrine 50 mL vials are on back order and the company estimates a release date of mid-May 2018. The 0.5% bupivacaine with epinephrine 10 mL preservative-free vials are on back order and the company estimates a release date of March 2019. The 0.5% bupivacaine with epinephrine 30 mL preservative-free vials are on back order and the company estimates a release date of mid-June 2018. The 0.5% bupivacaine with epinephrine 50 mL vials are on back order and the company estimates a release date of June 2018. Pfizer has 0.25% bupivacaine with epinephrine 10 mL preservative-free NOVAPLUS vials on back order and the company estimates a release date of September 2018.
- Pfizer has 0.25% Marcaine with epinephrine 10 mL and 30 mL preservative-free vials on back order and the company estimates a release date of March 2019. The 0.25% Marcaine with epinephrine 50 mL vials are on back order and the company estimates a release date of March 2019. The 0.5% Marcaine with epinephrine 10 mL and 30 mL preservative-free vials are on back order and the company estimates a release date of March 2019. The 0.5% Marcaine with epinephrine 50 mL vials are on back order and the company estimates a release date of March 2019.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=261>

**Bupivacaine Injection****April 12, 2018**

## Reason for the Shortage

- AuroMedics has not provided a reason for the shortage.
- Fresenius Kabi had Sensorcaine on shortage due to increased demand for the product.
- Pfizer has bupivacaine on shortage due to manufacturing delays. Pfizer discontinued 0.5% bupivacaine 30 mL glass ampules in December 2017.

## Estimated Resupply Dates

- AuroMedics has 0.25% bupivacaine 10 mL and 30 mL preservative-free vials on intermittent back order and the company is releasing product as it becomes available. The 0.5% bupivacaine 10 mL and 30 mL preservative-free vials are on intermittent back order and the company is releasing product as it becomes available.
- Fresenius Kabi has 0.25% Sensorcaine 30 mL preservative-free vials on back order and the company estimates a release date of mid-May 2018. The 0.25% 50 mL vials are on back order and the company estimates a release date of late-April 2018. The 0.5% Sensorcaine 10 mL and 30 mL preservative-free vials are on back order and the company estimates a release date of mid-May 2018. The 0.5% Sensorcaine 50 mL vials are on back order and the company estimates a release date of late-April 2018. The 0.25% and 0.5% Sensorcaine 30 mL preservative-free vials in sterile packs are on back order and the company cannot estimate a release date.
- Pfizer has 0.25% bupivacaine 10 mL preservative-free vials on back order and the company estimates a release date of June 2018. The 0.25% bupivacaine 50 mL vials are on back order and the company estimates a release date of late-June 2018. The 0.5% bupivacaine 10 mL and 30 mL preservative-free vials are on back order and the company estimates a release date of late-June 2018 for the 10 mL vials and mid-May 2018 for the 30 mL vials. The 0.5% bupivacaine 50 mL vials are on back order and the company estimates a release date of late-April 2018.
- Pfizer has all Marcaine presentations on back order and the company estimates a release date of March 2019 except for the bupivacaine 0.75% in 8.25% dextrose 2 mL ampules are on back order with an estimated release date of June 2018.
- Pfizer has bupivacaine 0.75% in 8.25% dextrose 2 mL ampules on back order and the company estimates a release date of mid-May 2018.
- Baxter has bupivacaine 0.75% in 8.25% dextrose 2 mL ampules on back order and the company estimates a release date of mid-April 2018.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=172>

**Yellow Fever Vaccine****April 11, 2018**

## Reason for the Shortage

- Sanofi Pasteur states the shortage is due to production delays. [1]
- There are no other suppliers of yellow fever vaccine.
- Additional information on the yellow fever shortage is available at <http://wwwnc.cdc.gov/travel/news-announcements/yellow-fever-vaccine-shortage-2015>.

## Estimated Resupply Dates

- Sanofi Pasteur has YF-Vax multi-dose vials and single dose vials on back order and the company estimates a release date in late-2018.[1]
- FDA accepted an investigational new drug application in October 2016. This is for the importation of another yellow fever vaccine from France. The trade name of the imported product is Stamaril. The product information can be found at [https://s3.amazonaws.com/filecache.drivetheweb.com/mr5str\\_sanofipasteur/202281/969800.pdf](https://s3.amazonaws.com/filecache.drivetheweb.com/mr5str_sanofipasteur/202281/969800.pdf). The initial rollout began in April 2017. More information can be found at [https://www.cdc.gov/mmwr/volumes/66/wr/mm6617e2.htm?s\\_cid=mm6617e2\\_w](https://www.cdc.gov/mmwr/volumes/66/wr/mm6617e2.htm?s_cid=mm6617e2_w) or at <https://www.vaccineshoppe.com/index.cfm?fa=anon.content&n=YellowFever&title=>.  
<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=197>

### Sterile Water For Injection - Small Volume Vials

**April 11, 2018**

#### Reason for the Shortage

- Pfizer has sterile water for injection in vials on shortage due to manufacturing delays.
- Fresenius Kabi has sterile water on shortage due to increased demand.

#### Estimated Resupply Dates

- Fresenius Kabi has sterile water for injection 5 mL, 10 mL, 20 mL, 50 mL, and 100 mL vials are on back order and the company estimates a release date of mid-June 2018 for the 5 mL vials, mid-April 2018 for the 10 mL vials, early- to mid-May 2018 for the 20 mL vials, mid-April 2018 for the 50 mL vials, and late-May 2018 for the 100 mL vials. Check wholesalers for inventory.
- Pfizer has sterile water for injection 10 mL, 20 mL, 50 mL, and 100 mL vials on allocation.  
<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=375>

### Multiple Vitamin Oral Liquid

**April 11, 2018**

#### Reason for the Shortage

- Major has discontinued CertaVite with Antioxidants.
- Pfizer has Centrum liquid available.
- Rugby has Cerovite liquid on shortage due to the PharmaTech recall in August 2017. Several products were recalled due to potential contamination with Burkholderia cepacia.

#### Estimated Resupply Dates

- Rugby has Cerovite liquid unavailable. The company plans to re-launch Cerovite in mid-June 2018. The product will have a new NDC number (00536-1153-59).  
<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=392>

### Mannitol Injection

**April 11, 2018**

#### Reason for the Shortage

- American Regent did not provide a reason for the mannitol shortage.
- Baxter did not provide a reason for the mannitol shortage.
- Fresenius Kabi has mannitol on shortage due to increased demand.

- Pfizer has mannitol on shortage due to manufacturing delays.

#### Estimated Resupply Dates

- American Regent has mannitol 250 mg/mL 50 mL vials on back order and the company cannot estimate a release date.
- Fresenius Kabi has mannitol 250 mg/mL 50 mL vials on back order and the company estimates a release date of mid- to late-June 2018. Check wholesalers for supply.
- Pfizer has mannitol 250 mg/mL 50 mL vials on back order and the company estimates a release date of April 2018.
- BBraun has mannitol 200 mg/mL 250 mL and 500 mL premixed bags on allocation to current customers.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=341>

#### Lactated Ringer's Injection

**April 11, 2018**

#### Reason for the Shortage

- Baxter did not provide a reason for the shortage.
- BBraun states the reason for the shortage is increased demand.
- ICU Medical states the reason for the shortage is increased demand.

#### Estimated Resupply Dates

- Baxter has lactated ringer's 250 mL and 500 mL bags on back order and the company estimates a release date in late-April 2018 for the 250 mL bags and mid-April 2018 for the 500 mL bags. Lactated ringer's with 5% dextrose 500 mL bags are on back order and the company cannot estimate a release date.
- BBraun has lactated ringer's injection solution and lactated ringer's with 5% dextrose injection solution products on allocation to current customers.
- ICU Medical has lactated ringer's 250 mL and 500 mL bags and lactated ringer's with 5% dextrose 500 mL on back order and the company estimates a release date of early-May 2018 for the 250 mL bags and late-April 2018 for the 500 mL bags.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=361>

#### Isocarboxazid Tablets

**April 11, 2018**

#### Reason for the Shortage

- Validus has Marplan tablets on shortage due to manufacturing delays.

#### Estimated Resupply Dates

- Validus has Marplan on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=411>

**Furosemide Tablets****April 11, 2018**

## Reason for the Shortage

- Major states the shortage is due to supply and demand issues.
- Mylan and Teva did not provide a reason for the shortage.
- West-Ward states the shortage is due to manufacturing delays.
- Sandoz discontinued furosemide tablets in late-August 2017.

## Estimated Resupply Dates

- Mylan has furosemide 40 mg tablets in 100 count and 1000 count on back order and the company estimates a release date of early-May 2018.
- Teva has furosemide 20 mg and 40 mg tablets in 100 and 1000 count bottles temporarily unavailable and the company cannot estimate a release date.
- West-Ward has furosemide 20 mg tablets in 100 count and 1000 count bottles on allocation. The 40 mg tablets in 100 count and 1000 count bottles are on allocation.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=339>

**Dopamine Hydrochloride Injection****April 11, 2018**

## Reason for the Shortage

- American Regent has dopamine on shortage due to manufacturing delays.
- Baxter has dopamine on shortage due to manufacturing delays.
- Pfizer states the shortage is due to manufacturing delays. The dopamine 200 mg/250 mL and 400 mg/500 mL premixed bags were discontinued in August 2017.

## Estimated Resupply Dates

- American Regent has all dopamine presentations on back order and the company cannot estimate a release date.
- Baxter has dopamine 800 mg/500 mL bags on back order and the company cannot estimate a release date.
- Pfizer has dopamine 40 mg/mL 10 mL vials on back order and the company estimates a release date of June 2019. The 400 mg/250 mL bags are on back order and the company estimates a release date of late-April 2018. The 800 mg/250 mL premixed bags are on back order and the company estimates a release date of early-May 2018. The 800 mg/500 mL bags are on back order and the company estimates a release date of early-May 2018. The 40 mg/mL 5 mL vials are on back order and the company estimates a release date of mid-May 2018.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=246>

**Ampicillin Sodium and Sulbactam Sodium Injection****April 11, 2018**

## Reason for the Shortage

- Pfizer has discontinued generic ampicillin sulbactam except for the 1.5 gram and 3 gram ADD-Vantage vials. These are on shortage due to manufacturing delays.
- Sagent had ampicillin sulbactam vials on back order due to manufacturing delays.

- Sandoz cannot provide a reason for the shortage.
- WG Critical Care states the shortage was due to increased demand.

#### Estimated Resupply Dates

- AuroMedics has ampicillin sulbactam 1.5 gram, 3 gram, and 15 gram vials on long-term back order and the company cannot estimate a release date.
- Fresenius Kabi has ampicillin sulbactam 1.5 gram, 3 gram, and 15 gram vials on long-term back order and the company cannot estimate a release date.
- Mylan Institutional has ampicillin sulbactam 1.5 gram vials on back order and the company estimates a release date of mid-April 2018.
- Pfizer has ampicillin sulbactam 1.5 gram and 3 gram ADD-Vantage vials on back order and the company estimates a release date of late-June 2018.
- Sandoz has ampicillin sulbactam 1.5 gram, 3 gram, and 15 gram vials temporarily unavailable and the company cannot estimate a release date.
- West-Ward has ampicillin sulbactam 3 gram vials on allocation. The 15 gram vials are on back order and the company estimates a release date of May to June 2018.
- WG Critical Care has ampicillin sulbactam 1.5 gram vials on back order and the company estimates a release date of late-April 2018.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=159>

### Alcohol Dehydrated Injection (Ethanol)

**April 11, 2018**

#### Reason for the Shortage

- Akorn states the back order was due to manufacturing delays.
- Flon Laboratoris has dehydrated alcohol available through Morris and Dickson and direct orders. The customer service number is 877-358-4342. It is being marketed by MHC Pharma, LLC.

#### Estimated Resupply Dates

- American Regent has dehydrated alcohol 1 mL and 5 mL ampules on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=274>

### Lidocaine with Epinephrine Injection

**April 10, 2018**

#### Reasons for the Shortage

- Fresenius Kabi has Xylocaine with epinephrine presentations on shortage due to increased demand for the product and manufacturing delays.
- Pfizer has lidocaine with epinephrine presentations on shortage due to manufacturing delays.

#### Estimated Resupply Dates

- Pfizer has 0.5% lidocaine with epinephrine (1:200,000) 50 mL on back order and the company estimates a release date of mid-May 2018. The 1% lidocaine with epinephrine (1:100,000) 20 mL vials are on back order and the company estimates a release date of late-May 2018. The 1% lidocaine with epinephrine (1:100,000) 30 mL are on back order and the company estimates a release date of late-April 2018. The 1% lidocaine with epinephrine (1:100,000) 50 mL vials are on



back order and the company estimates a release date of mid-April 2018. The 1.5% lidocaine with epinephrine (1:200,000) 30 mL vials are on back order and the company estimates a release date of September 2018. The 2% lidocaine with epinephrine (1:200,000) 20 mL vials are on back order and the company estimates a release date of late-April 2018. The 2% lidocaine with epinephrine (1:100,000) 20 mL, 30 mL, and 50 mL vials are on back order and the company estimates a release date of June 2018 for the 20 mL and 30 mL vials and April 2018 for the 50 mL vials.

- Fresenius Kabi has 0.5% Xylocaine with epinephrine (1:200,000) 50 mL vials on back order and the company cannot estimate a release date. The 1% Xylocaine with epinephrine (1:200,000) 10 mL vials are on back order and the company cannot estimate a release date. The 1% Xylocaine with epinephrine (1:200,000) 20 mL and 50 mL vials are on back order and the company estimates a release date of mid-April 2018. The 1% Xylocaine-MPF with epinephrine (1:200,000) 10 mL and 30 mL vials are on back order and the company estimates a release date of late-April 2018 for the 10 mL vials and late-May 2018 for the 30 mL vials. The 1% Xylocaine-MPF with epinephrine (1:200,000) 30 mL vials in sterile packs are on back order and the company cannot estimate a release date. The 1.5% Xylocaine-MPF with epinephrine (1:200,000) 30 mL vials are on back order and the company estimates a release date of mid-April 2018. The 1.5% Xylocaine-MPF with epinephrine (1:200,000) 10 mL regular vials and 30 mL vials in sterile packs are on back order and the company cannot estimate a release date. The 2% Xylocaine with epinephrine (1:200,000) 20 mL vials are on back order and the company and the company estimates a release date of mid-April 2018. The 2% Xylocaine with epinephrine (1:200,000) 50 mL vials are on back order and the company estimates a release date of mid-May 2018. The 2% Xylocaine-MPF with epinephrine (1:200,000) 20 mL vials are on back order and the company estimates a release date of mid-April 2018. The 2% Xylocaine-MPF with epinephrine (1:200,000) 10 mL vials and 20 mL vials in sterile packs are on back order and the company cannot estimate a release date. Check wholesalers for inventory.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=98>

### Lidocaine Injection

**April 10, 2018**

#### Reason for the Shortage

- Amphastar had lidocaine 2% emergency syringes on shortage due to increase demand for the product.
- AuroMedics introduced lidocaine injection in February 2014.
- Fresenius Kabi had generic lidocaine presentations on shortage due to a supply interruption of raw ingredients.
- Pfizer has lidocaine presentations on shortage due to manufacturing delays.

#### Estimated Resupply Dates

- AuroMedics has 1% lidocaine 2 mL and 5 mL ampules and 2mL, 5 mL, and 30 mL vials on intermittent back order and the company is releasing product as it becomes available. AuroMedics has 2% lidocaine 2mL ampules and 5 mL vials on intermittent back order and the company is releasing product as it becomes available.
- Fresenius Kabi has 0.5% Xylocaine and 0.5% Xylocaine-MPF 50 mL vials on back order and the company estimates a release date of mid-April 2018. The 1% lidocaine 10 mL vials are on back order and the company estimates a release date of mid-April 2018. The 1% Xylocaine 20 mL and 50 mL vials are on back order and the company estimates a release date of mid-April 2018. The 1% Xylocaine-MPF 2 mL vials are on back order and the company estimates a release date of late-April to early-May 2018. The 1% Xylocaine-MPF 5 mL vials are on back order and the company cannot

estimate a release date. The 1% Xylocaine-MPF 10 mL vial sterile packs are on back order and the company estimates a release date of late-April 2018. The 1% Xylocaine-MPF 30 mL vial sterile packs are on back order and the company cannot estimate a release date. The 2% Xylocaine-MPF 2 mL and 5 mL vials are on back order and the company estimates a release date of mid-April 2018 for the 2 mL vials and late-April 2018 for the 5 mL vials. The 2% Xylocaine-MPF 10 mL ampules are on back order and the company estimates a release date of early-May 2018. The 2% Xylocaine 10 mL, 20 mL, and 50 mL vials are on back order and the company estimates a release date of mid-May 2018 for the 10 mL vials and mid-April 2018 for the 20 mL and 50 mL vials. The 2% lidocaine 5 mL preservative free vials are on back order and the company estimates a release date of mid-April 2018. Check wholesalers for inventory.

- Pfizer has 0.5% lidocaine 50 mL vials on back order and the company estimates a release date of June 2018. The 1% lidocaine 2 mL preservative-free ampules are on back order and the company estimates a release date of mid-April 2018. The 1% lidocaine 5 mL preservative-free ampules are on back order and the company estimates a release date of June 2019. The 1% lidocaine 20 mL vials are on back order and the company estimates a release date of mid-May 2018. The 1% lidocaine 30 mL preservative-free vials are on back order and the company estimates a release date of mid-May 2018. The 1% lidocaine 50 mL vials are on back order and the company estimates a release date of late-April 2018. The 1% lidocaine 5 mL Ansys syringes and 5 mL LifeShield syringes are on back order and the company estimates a release date of June 2018. The 2% lidocaine 2 mL preservative-free ampules are on back order and the company estimates a release date of late-July 2018. The 2% lidocaine 5 mL vials are on back order and the company estimates a release date of March 2019. The 2% lidocaine 20 mL vials are on back order and the company estimates a release date of mid-June 2018. The 2% lidocaine 50 mL vials are on back order and the company estimates a release date of early-May 2018. The 2% lidocaine 5 mL Lifeshield syringes and 5 mL Ansys syringes are on back order and the company estimates a release date of late-April 2018. The 4% lidocaine 5 mL ampules are on back order and the company estimates a release date of late-April 2018.
- West-Ward has 1% lidocaine 5 mL preservative-free vials, 1% lidocaine 50 mL vials, and 2% lidocaine 5 mL preservative free vials on allocation. The 2% lidocaine 50 mL vials are on back order and the company estimates a release date of May to June 2018.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=88>

### Hydromorphone Hydrochloride Injection

**April 10, 2018**

#### Reason for the Shortage

- Akorn has hydromorphone injection on shortage due to increased demand.[1]
- Fresenius Kabi has Dilaudid syringes on shortage due to increased demand. They are focusing their product on the 0.5 mg strength.[2]
- Pfizer did not provide a reason for the shortage.[3]
- Purdue discontinued Dilaudid and Dilaudid HP in May 2017 for marketing reasons.[4]
- Teva did not provide a reason for the shortage.[5]
- West-Ward did not provide a reason for the shortage.[6]

#### Estimated Resupply Dates

- Akorn has hydromorphone 10 mg/mL 1 mL ampules, 5 mL ampules, and 50 mL vials on allocation.[1]

- Fresenius Kabi has Dilaudid 0.5 mg/mL 0.5 mL syringes on back order and the company estimates a release date of late-April 2018. The 1 mg/mL 1 mL syringes and 2 mg/mL 1 mL syringes are on back order and the company cannot estimate a release date.[2]
- Pfizer has 2 mg/mL 1 mL vials on back order and the company estimates a release date of late-April 2018. The 10 mg/mL 1 mL vials are on back order and the company estimates a release date of late-April 2018. The 10 mg/mL 5 mL are on back order and the company estimates a release date of September 2018. The 10 mg/mL 50 mL vials are on back order and the company estimates a release date of late-June 2018. The 1 mg/mL 1 mL Carpuject syringes, 2 mg/mL 1 mL Carpuject syringes, 0.5 mg/0.5 mL 0.5 mL iSecure syringes, 1 mg/mL 1 mL ampules, 2 mg/mL 1 mL ampules, and 4 mg/mL 1 mL ampules are on back order and the company cannot estimate a release date. The 1 mg/mL 1 mL iSecure syringes, 2 mg/mL 1 mL iSecure syringes, and 4 mg/mL 1 mL Carpuject syringes are on back order and the company estimates a release date of June 2019.[3]
- Teva has hydromorphone 10 mg/mL 1 mL, 5 mL, and 50 mL vials on intermittent back order and the company is allocating product upon release.[5]
- West-Ward has hydromorphone 2 mg/mL 1 mL vials on allocation. The 2 mg/mL 20 mL vials are on back order and the company estimates a release date of mid-April to early-May 2018.[6]

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=329>

### Heparin Injection

**April 10, 2018**

#### Reason for the Shortage

- Fresenius Kabi did not provide a reason for the shortage.
- Pfizer did not provide a reason for the shortage.
- Sagent has all heparin presentations available.
- West-Ward did not provide a reason for the shortage.

#### Estimated Resupply Dates

- Pfizer has 10,000 unit/mL 0.5 mL Carpuject syringes on back order and the company cannot estimate a release date. The 5000 unit/mL 1 mL Carpuject syringes are on back order and the company estimates a release date of June 2019. The 1000 unit/mL 10 mL vials, 10,000 unit/mL 1 mL vials, and 1000 unit/mL 30 mL vials are on back order and the company cannot estimate a release date.
- Sagent has 10,000 unit/mL 1 mL vials on back order and the company estimates a release date of April 2018. The 1000 unit/mL 2 mL and 10 mL vials are on allocation.
- West-Ward has 1000 unit/mL 30 mL vials and 5000 unit/mL 10 mL vials on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=353>

### Cisplatin Injection

**April 10, 2018**

#### Reason for the Shortage

- Athenex has cisplatin available.[1]
- Fresenius Kabi has cisplatin available.[2]
- Mylan Institutional discontinued cisplatin in January 2018.[3]
- Teva had cisplatin on allocation due to increased demand.[4]

- WG Critical Care has cisplatin available.[5]

#### Estimated Resupply Dates

- Fresenius Kabi has cisplatin 1 mg/mL 100 mL vials on back order with an estimated release date of late-April 2018, and 1 mg/mL 200 mL vials on back order with an estimated release date of mid-April 2018. The 1 mg/mL 50 mL vials are available with short-expiration dating of <8 months.[2]
- WG Critical Care has 1 mg/mL 100 mL vials available with short-expiration dating of <12 months. Additional supply has an estimated release date of late-April 2018.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=96>

### Atenolol Tablets

**April 10, 2018**

#### Reason for the Shortage

- Mylan, Sandoz, and Teva did not provide a reason for the back order.
- Zydus states increased demand as the reason for the back order.
- Ranbaxy refuses to provide us with any information regarding drug availability.
- Major discontinued atenolol 25 mg unit-dose tablets.

#### Estimated Resupply Dates

- Sandoz has all atenolol tablets temporarily unavailable and the company cannot estimate a release date.
- Teva has atenolol 25 mg in 100 count and 50 mg in 1000 count on back order and the company estimates a release date of late-April 2018.
- Almatica has Tenormin 100 mg tablets on back order and the company cannot estimate a release date. The 25 mg and 50 mg tablets are on allocation.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=334>

### Multiple Vitamins for Infusion

**April 9, 2018**

#### Reason for the Shortage

- Pfizer states the shortage is due to manufacturing delays.
- Baxter has all presentations fully available at this time.

#### Estimated Resupply Dates

- Pfizer has M.V.I. adult 50 mL Dual vials on back order and the company estimates a release date of late-April 2018. The M.V.I. 2 x 5 mL Dual vials and 5 mL pediatric vials are available in limited supply.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=69>

### Mitoxantrone Hydrochloride Injection

**April 9, 2018**

#### Reason for the Shortage

- Fresenius Kabi has mitoxantrone available.[1]
- Pfizer has mitoxantrone injection on shortage due to manufacturing delays.[2]

- Teva has mitoxantrone injection available except for the 10 mL vials which are temporarily discontinued.[3]

#### Estimated Resupply Dates

- Pfizer has mitoxantrone 2 mg/mL 10 mL vials on back order and the company estimates a release date of mid-May 2018.[2]
- Teva has temporarily discontinued mitoxantrone 10 mL vials and the company cannot estimate a release date.[3]

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=189>

### Mepivacaine Injection

**April 9, 2018**

#### Reason for the Shortage

- Fresenius Kabi has Polocaine and Polocaine-MPF available.
- Pfizer states the reason for the shortage is manufacturing delays.

#### Estimated Resupply Dates

- Pfizer has Carbocaine 2% 20 mL preservative-free vials, 1% 30 mL preservative-free vials, 1% 50 mL multiple-dose vials, and 1.5% 30 mL preservative-free vials on back order and the company estimates a release date of March 2019.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=331>

### Chlorothiazide Sodium Injection

**April 9, 2018**

#### Reason for the Shortage

- Akorn has chlorothiazide injection on shortage due to manufacturing delays.
- Sagent has chlorothiazide injection on shortage due to increased demand.
- Sun Pharma refuses to provide availability information on any of their products.

#### Estimated Resupply Dates

- American Regent has chlorothiazide 500 mg vials on back order and the company cannot estimate a release date.
- Fresenius Kabi has chlorothiazide 500 mg vials on back order and the company estimates a release date of mid-April 2018.
- Mylan Institutional has chlorothiazide 500 mg vials on back order and the company estimates a release date of early- to mid-April 2018.
- Sagent has chlorothiazide 500 mg vials on allocation.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=365>

### Amino Acid Products

**April 9, 2018**

#### Reason for the Shortage

- Baxter has most amino acid products on allocation due to delays because of Hurricane Maria in Puerto Rico. [1]

- BBraun has all amino acid on allocation due to increased demand.[2]
- Pfizer has Aminosyn on back order due to an ingredient shortage which has caused a supply disruption. Pfizer has obtained the ingredient, but does not yet have an estimated date as to when manufacturing will resume.[3]

#### Estimated Resupply Dates

- Baxter has their amino acid products on allocation.[1]
- BBraun has their amino acid products on allocation.[2]
- ICU Medical has Aminosyn II 15% 2000 mL bags and 10% 2000 mL bags on back order and the company estimates a release date of late-April 2018. These are not restricted to current customers. All other Aminosyn presentations are on back order and the company estimates a release date in 1st quarter 2019.[3]

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=297>

### Oseltamivir Oral Suspension

**April 6, 2018**

#### Reason for the Shortage

- Alvogen had oseltamivir oral powder for suspension on shortage due to increased demand.
- Zydus had oseltamivir oral powder for suspension on shortage due to increased demand.
- Genentech has Tamiflu oral powder for suspension available.
- The oral capsules are not affected by this shortage.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=383>

### Ketorolac Injection

**April 6, 2018**

#### Reason for the Shortage

- Alvogen has ketorolac injection available in 25 count sizes.[1]
- Amphastar did not provide a reason for the shortage.[2]
- Athenex has ketorolac injection available.[3]
- BD RX is now part of Fresenius Kabi.[4]
- Fresenius Kabi did not provide a reason for the shortage.[5]
- Pfizer has ketorolac injection on back order due to manufacturing delays.[6]
- Sagent states the reason for the shortage is manufacturing delay.[7]
- West-Ward is not actively marketing ketorolac injection.[8]
- Ben Venue closed its plant in Bedford, Ohio in July 2014.[9]
- Virtus has ketorolac injection available.[10]
- FDA imposed an import ban in mid-2013 on several Wockhardt products including ketorolac.[11]
- Sprix Nasal Spray is not affected by this shortage.[12]

#### Estimated Resupply Dates

- Amphastar has ketorolac 30 mg/mL 1 mL vials on back order and the company cannot estimate a release date.[2]
- Fresenius Kabi has ketorolac 15 mg/mL 1 mL vials on back order and the company estimates a release date of late-April 2018.[5]

- Pfizer has ketorolac 15 mg/mL 1 mL vials on back order and the company estimates a release date in late-April 2018. The 30 mg/mL 1 mL Carpuject syringes, 30 mg/mL 2 mL Carpuject syringes for intramuscular injection, and 30 mg/mL 1 mL iSecure syringes are on back order and the company estimates a release date of June 2019. The 30 mg/mL 1 mL vials are on intermittent back order and the company is releasing supplies as they become available.[6]
- Sagent has ketorolac 30 mg/mL 2 mL vials for intramuscular injection on back order and the company estimates a release date in April 2018. The 15 mg/mL 1 mL vials are on back order and the company estimates a release date in April 2018.[7]

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=113>

### Thiotepa For Injection

**April 5, 2018**

#### Reason for the Shortage

- West-Ward launched thiotepa in August 2015. West-Ward has product available.
- Amneal launched Tepadina in early 2017.

#### Estimated Resupply Dates

- All marketed presentations are available.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=117>

### Sufentanil Injection

**April 5, 2018**

#### Reason for the Shortage

- Pfizer has sufentanil injection on shortage due to manufacturing delays.
- Akorn has Sufenta injection on shortage due to increased demand for the product.
- West-Ward did not provide a reason for the shortage.

#### Estimated Resupply Dates

- Pfizer has sufentanil 50 mcg/mL 1 mL and 2 mL vials on back order and the company estimates a release date of late-June 2018 for the 1 mL vials and late-April 2018 for the 2 mL vials.
- Akorn has Sufenta 50 mcg/mL 1 mL, 2 mL, and 5 mL ampules on back order and the company estimates a release date of early-May 2018 for the 1 mL ampules and late-April 2018 for the 2 mL and 5 mL ampules.
- West-Ward has sufentanil 50 mcg/mL 5 mL ampules available with an expiration date of < July 2018.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=376>

### Progesterone Injection

**April 5, 2018**

#### Reason for the Shortage

- American Regent did not provide a reason for the shortage.
- Fresenius Kabi has progesterone on shortage due to increased demand and manufacturing delays.
- Teva has progesterone on shortage due to supply constraints.
- West-Ward has progesterone on shortage due to manufacturing delays.

#### Estimated Resupply Dates

- American Regent has progesterone in oil 50 mg/mL 10 mL vials for intramuscular injection on back order and the company cannot estimate a release date.
- Fresenius Kabi has progesterone in oil 50 mg/mL 10 mL vials for intramuscular injection on back order and the company estimates a release date of 2nd quarter 2018. Check wholesaler for availability.
- Teva has progesterone in oil 50 mg/mL 10 mL vials for intramuscular injection on back order and the company estimates a release date of late-April 2018.
- West-Ward has progesterone in oil 50 mg/mL 10 mL vials for intramuscular injection on allocation.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=381>

#### Moxifloxacin Injection

**April 5, 2018**

#### Reason for the Shortage

- Bayer discontinued Avelox IV in December 2017.
- Fresenius Kabi has moxifloxacin injection on shortage due to increased demand.
- Mylan Institutional did not provide a reason for the shortage.

#### Estimated Resupply Dates

- Fresenius Kabi has moxifloxacin 400 mg/250 mL premixed bags on back order and the company estimates a release date of early-May 2018.
- Mylan Institutional has moxifloxacin 400 mg/250 mL premixed bags on back order and the company estimates a release date of late-April 2018.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=357>

#### Methylene Blue

**April 5, 2018**

#### Reason for the Shortage

- Akorn has methylene blue on shortage due to manufacturing delays.[1]
- American Regent has recently launched an FDA approved presentation, ProvayBlue and product is available.[2]

#### Estimated Resupply Dates

- Akorn has methylene blue 10 mg/mL 1 mL vials on back order and the company cannot estimate a release date.[1]

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=47>

#### Methadone Injection

**April 5, 2018**

#### Reason for the Shortage

- Mylan Institutional did not provide a reason for the shortage.

#### Estimated Resupply Dates



- Mylan Institutional has methadone 10 mg/mL 20 mL vials on back order and the company estimates a release date of early-May 2018.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=358>

### Lorazepam Injection

**April 5, 2018**

#### Reason for the Shortage

- Bedford discontinued lorazepam injection in May, 2011.[1]
- West-Ward has product on shortage due to manufacturing delays.[2]
- Pfizer has product on shortage due to increased demand and manufacturing delays. Pfizer discontinued 4 mg/mL 10 mL vials in December 2017.[3]
- Akorn has not provided a reason for the shortage.[4]
- Amphastar has product available.[5]

#### Estimated Resupply Dates

- Akorn has lorazepam 2 mg/mL 1 mL vials available in limited supply.[4]
- Pfizer has lorazepam 2 mg/mL 1 mL Carpuject syringes on back order and the company cannot estimate a release date. The 2 mg/mL 1 and 10 mL vials are on back order and the company estimates a release date of mid-May 2018 for the 1 mL vials and June 2018 for the 10 mL vials. The 4 mg/mL 1 mL vials are on back order and the company estimates a release date of early-May 2018. The 4 mg/mL 1 mL Carpuject syringes are on back order and the company estimates a release date of June 2019.[3]
- West-Ward has lorazepam 2 mg/mL 1 mL vials on allocation. The 2 mg/mL 10 mL vials are on back order and the company estimates a release date of mid-April to early-May 2018. The 4 mg/mL 1 mL vials are on back order and the company estimates a release date of mid-April to early-May 2018. The 4 mg/mL 10 mL vials are on allocation.[2]
- West-Ward has Ativan 2 mg/mL 1 mL and 10 mL vials on back order and the company estimates a release date of April 2018 for the 1 mL vials and April to May 2018 for the 10 mL vials. Ativan 4 mg/mL 1 mL and 10 mL vials are on back order and the company estimates a release date of April 2018.[2]

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=87>

### Indomethacin Capsules

**April 5, 2018**

#### Reason for the Shortage

- Glenmark had indomethacin on shortage due to manufacturing delays.
- Heritage discontinued all indomethacin presentations in early 2018.
- Mylan did not provide a reason for the shortage.
- Sandoz discontinued indomethacin in mid-2016.
- Teva did not provide a reason for the shortage.

#### Estimated Resupply Dates

- Mylan has indomethacin 25 mg capsules in 100 count on back order and the company estimates a release date of late-June 2018. The 50 mg capsules in 100 count unit-dose are on back order and the

company estimates a release date of early-August 2018. The 50 mg capsules in 500 count are on back order and the company estimates a release date of mid-July 2018.

- Teva has all indomethacin presentations temporarily unavailable and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=235>

### Fentanyl Citrate Injection

**April 5, 2018**

#### Reason for the Shortage

- Akorn has fentanyl injection on shortage due to increased demand.
- West-Ward has fentanyl injection on shortage due to supply and demand issues.
- Pfizer has fentanyl injection on shortage due to manufacturing delays. The 20 mL ampules were discontinued in September 2017.

#### Estimated Resupply Dates

- Akorn has Sublimaze 50 mcg/mL 2 mL ampules in 10 count on intermittent back order and is allocating product upon release. Sublimaze 50 mcg/mL 2 mL ampules in 25 count and 5 mL ampules in 10 count and 25 count are on allocation.
- Pfizer has fentanyl 50 mcg/mL 2 mL and 5 mL ampules on back order and the company estimates a release date of mid-April 2018 for the 2 mL ampules and late-April 2018 for the 5 mL ampules. The 2 mL Carpuject syringes are on back order and the company estimates a release date of June 2019. The 2 mL, 5 mL, 10 mL, 20 mL, and 50 mL vials are on back order and the company estimates a release date of late-April 2018 for the 2 mL and 5 mL vials, June 2018 for the 10 mL vials, and late-April 2018 for the 20 mL and 50 mL vials.
- West-Ward has fentanyl 50 mcg/mL 2 mL and 50 mL vials on allocation. The 5 mL and 20 mL vials are on back order and the company estimates a release date of mid-April to early-May 2018. The 2 mL, 5 mL, and 20 mL ampules are on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=315>

### Amiodarone Injection

**April 5, 2018**

#### Reason for the Shortage

- Baxter had Nexterone premixed bags on shortage due to manufacturing delays.
- Mylan Institutional did not provide a reason for the shortage.
- West-Ward did not provide a reason for the shortage.

#### Estimated Resupply Dates

- West-Ward has amiodarone 50 mg/mL 3 mL vials in 25 count on back order and the company estimates a release date of May to June 2018.
- Mylan Institutional has amiodarone 50 mg/mL 3 mL and 18 mL vials on back order and the company estimates a release date of late-May 2018 for the 3 mL vials and early-May 2018 for the 18 mL vials. The amiodarone 50 mg/mL 9 mL vials are on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=374>

**2% Lidocaine Hydrochloride Topical Jelly****April 5, 2018**

## Reason for the Shortage

- Akorn has 2% lidocaine jelly on shortage due to increased demand.
- Teva did not provide a reason for the shortage. Teva discontinued the 30 mL size in early-2018.
- Glydo and Uro-Jet prefilled syringes are not affected by this shortage.

## Estimated Resupply Dates

- Akorn has 2% lidocaine jelly 5 mL and 30 mL tubes on allocation.
- Teva has 2% lidocaine jelly 5 mL tubes on back order and the company estimates a release date of late-April 2018.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=400>

**Procainamide Hydrochloride Injection****April 2, 2018**

## Reason for the Shortage

- Pfizer has procainamide injection on shortage due to manufacturing delays.
- Nexus Pharmaceuticals launched procainamide injection in October 2017.

## Estimated Resupply Dates

- All marketed presentations are available.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=312>

**Phenytoin Sodium****April 2, 2018**

## Reason for the Shortage

- West-Ward did not provide a reason for this shortage.
- X-Gen Pharmaceuticals discontinued their phenytoin sodium presentations in April 2017.

## Estimated Resupply Dates

- West-Ward has phenytoin sodium 100 mg/2 mL and 250 mg/5 mL vials on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=406>

**Octreotide Injection****April 2, 2018**

## Reason for the Shortage

- Fresenius Kabi has octreotide available.
- Mylan Institutional has octreotide available.
- Sagent has octreotide on shortage due to manufacturing delays.
- Sun Pharma did not provide a reason for the shortage.
- Teva has octreotide available.
- Novartis has Sandostatin available.

- West-Ward has octreotide available.

#### Estimated Resupply Dates

- Fresenius Kabi has octreotide 50 mcg/mL 1 mL vials on back order and the company estimates a release date of 2nd quarter 2018.
- Sagent has octreotide 1,000 mcg/mL 5 mL vials on back order and the company estimates a release date of April 2018.
- Sun Pharma has all octreotide presentations on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=229>

#### 5% Dextrose Injection (Pvc-Free and Dehp-Free)

**April 2, 2018**

#### Reason for the Shortage

- ICU Medical states the shortage is due to increased demand and manufacturing delays. ICU Medical discontinued the 500 mL VisiV bags in 2011 due to leaking around the administration and medications ports.
- ICU Medical is now the IV fluid business of Pfizer after the acquisition of Hospira.
- Baxter is not currently marketing 5% dextrose PVC/DEHP-free bags.
- BBraun has 250 mL, 500 mL, and 1,000 mL PVC/DEHP-free bags on back order due to manufacturing delays.

#### Estimated Resupply Dates

- BBraun has 5% dextrose 250 mL, 500 mL, and 1,000 mL PVC/DEHP-free bags on allocation to current customers.
- ICU Medical has 5% dextrose in 100 mL and 250 mL PVC/DEHP-free bags on back order and the company estimates a release date in early-April 2018.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=314>

#### 5% Dextrose Injection

**April 2, 2018**

#### Reason for the Shortage

- ICU Medical states the shortage was due to increased demand.
- ICU Medical is now the IV fluid business of Pfizer after the acquisition of Hospira.
- Baxter did not provide a reason for the shortage.
- 5% dextrose 1,000-mL bags are not affected at this time.

#### Estimated Resupply Dates

- Baxter has 5% dextrose 250 mL bags on allocation. The 500 mL bags are on back order and the company cannot estimate a release date. The 1,000 mL bags are on back order and the company estimates a release date of early-April 2018.
- ICU Medical has 5% dextrose 250 mL ADD-Vantage bags and 250 mL 2 port bags (NDC 00409-7922-02) available in limited supply. The 250 mL 2 port bags (NDC 00409-7922-53) are on back order and the company estimates a release date in early-April 2018.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=303>

**Azithromycin Injection****April 4, 2018**

## Reason for the Shortage

- Pfizer has azithromycin injection on shortage due to manufacturing delays.
- AuroMedics did not provide a reason for the shortage.
- Sun Pharma did not provide a reason for the shortage.

## Estimated Resupply Dates

- AuroMedics has azithromycin 500 mg vials on intermittent back order and the company is releasing product as it becomes available.
- Pfizer has azithromycin 500 mg ADD-Vantage vials on back order and the company estimates a release date of June 2018.
- Sun Pharma has azithromycin 500 mg vials on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=380>

**Potassium Acetate Injection****March 31, 2018**

## Reason for the Shortage

- American Regent has not had product available for several years. It is unclear if they will market potassium acetate again in the future.
- Pfizer has potassium acetate on shortage due to manufacturing delays.

## Estimated Resupply Dates

- Pfizer has potassium acetate 2 mEq/mL 20 mL vials available in limited supply.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=344>

**Etomidate Injection****March 31, 2018**

## Reason for the Shortage

- American Regent did not provide a reason for the current shortage.
- AuroMedics did not provide a reason for the current shortage.
- Mylan did not provide a reason for the current shortage.
- Par Sterile Products discontinued etomidate in early 2015.
- Pfizer has Amidate on shortage due to manufacturing delays. Pfizer discontinued etomidate ampules in October 2016.
- Sagent is no longer marketing etomidate.
- West-Ward did not provide a reason for the current shortage.
- Zydus had etomidate on shortage due to an increase in demand.

## Estimated Resupply Dates

- American Regent has etomidate 2 mg/mL 10 mL and 20 mL vials on back order and the company cannot estimate a release date.

- AuroMedics has 2 mg/mL 10 mL vials on intermittent back order.
- Mylan Institutional has etomidate 2 mg/mL 10 mL and 20 mL vials on back order and the company estimates a release date of early-August 2018.
- Pfizer has Amidate 2 mg/mL 20 mL LifeShield syringes on back order and the company cannot estimate a release date. The 2 mg/mL 20 mL vials are available in limited supply.
- Zydus has etomidate 2 mg/mL 20 mL vials on intermittent back order.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=147>

### Dobutamine Injection

**March 31, 2018**

#### Reason for the Shortage

- Baxter has dobutamine on shortage due to manufacturing delays.
- Pfizer has dobutamine on shortage due to manufacturing delays.

#### Estimated Resupply Dates

- Baxter has dobutamine 4 mg/mL 250 mL bags on back order and the company cannot estimate a release date.
- Pfizer has dobutamine 12.5 mg/mL 20 mL and 40 mL latex-free vials on back order with an estimated release date of June 2019 for the 20 mL vials and 2018 for the 40 mL vials. The 12.5 mg/mL 20 mL regular vials in 1 count are on back order and the company estimates a release date of mid-May 2018. The 12.5 mg/mL 20 mL regular vials in 10 count are available in limited supply.
- Pfizer has dobutamine 1 mg/mL in 250 mL bags on back order and the company estimates a release date of early-May 2018. The dobutamine 2 mg/mL 250 mL bags are on back order and the company estimates a release date of late-May 2018. The dobutamine 4 mg/mL 250 mL bags are on back order and the company estimates a release date of early-June 2018.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=296>

### Diltiazem Hydrochloride Injection

**March 31, 2018**

#### Reason for the Shortage

- Akorn states the reason for the shortage was increased demand due to market conditions.
- Pfizer states the reasons for the shortage is manufacturing delays and increases in demand.
- West-Ward has diltiazem injection on shortage due to manufacturing delays caused by increased demand due to current market conditions.

#### Estimated Resupply Dates

- Akorn has diltiazem 5 mg/mL 5 mL and 10 mL vials on intermittent back order and is allocating product upon release. The 25 mL vials in 1 count and 10 count are on intermittent back order and the company is allocating product upon release.
- Pfizer has 100 mg ADD-Vantage vials available in limited supply. The 5 mg/mL 5 mL and 10 mL vials are on back order and the company estimates a release date of March 2019.
- West-Ward has diltiazem 5 mg/mL 5 mL vials on back order and the company estimates a release date of April 2018. The 10 mL and 25 mL vials are on allocation.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=26>

**25% Dextrose Injection****March 31, 2018**

## Reason for the Shortage

- Pfizer had 25% dextrose injection on shortage due to manufacturing delays.

## Estimated Resupply Dates

- Pfizer has 25% dextrose 10 mL Ansyx syringes available.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=322>

**Erythromycin Lactobionate Injection****March 22, 2018**

## Reason for the Shortage

- Pfizer has Erythrocin on shortage due to manufacturing delays.

## Estimated Resupply Dates

- Pfizer has Erythrocin 500 mg vials and 500 mg ADD-Vantage vials on back order and the company estimates a release date of September 2018.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=247>

**Lidocaine Hydrochloride and 5% Dextrose Injection****March 23, 2018**

## Reason for the Shortage

- Baxter did not provide a reason for the shortage.
- BBraun did not provide a reason for the shortage.

## Estimated Resupply Dates

- Baxter has lidocaine and 5% dextrose 4 mg/mL 500 mL and 8 mg/mL 250 mL premixed bags on back order and the company cannot estimate a release date.
- BBraun has lidocaine and 5% dextrose 4 mg/mL 250 mL, 4 mg/mL 500 mL, and 8 mg/mL 250 mL premixed bags on intermittent back order and supplies are being allocated upon release.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=372>

**Dipyridamole Injection****March 26, 2018**

## Reason for the Shortage

- West-Ward did not provide a reason for the shortage.

## Estimated Resupply Dates

- West-Ward has dipyridamole 5 mg/mL 10 mL vials on allocation.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=345>

**Ciprofloxacin Injection****March 26, 2018**

## Reason for the Shortage

- Pfizer has ciprofloxacin injection on shortage due to manufacturing delays.
- Baxter (formerly Claris) has ciprofloxacin injection available.

## Estimated Resupply Dates

- Pfizer has ciprofloxacin 2 mg/mL 100 mL and 200 mL premixed bags on back order and the company estimates a release date of May 2018 for the 100 mL premixed bags and early-May 2018 for the 200 mL premixed bags.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=396>

**Multiple Electrolytes Large Volume Solutions For Injection****March 28, 2018**

## Reason for the Shortage

- Baxter did not provide a reason for Plasma-Lyte 148 and Plasma-Lyte A back order.
- Pfizer had Normosol-R presentations on back order due to manufacturing delays.

## Estimated Resupply Dates

- Baxter has Plasma-Lyte-148 500 mL and 1,000 mL bags and Plasma-Lyte-A 500 mL bags available in limited quantities.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=389>

**Diclofenac 0.1% Ophthalmic Solution****March 28, 2018**

## Reason for the Shortage

- Akorn did not provide a reason for the shortage.
- Rising pharmaceuticals discontinued diclofenac ophthalmic solution.
- Sandoz did not provide a reason for the shortage.

## Estimated Resupply Dates

- Akorn has diclofenac 0.1% ophthalmic solution on long-term back order.
- Sandoz has diclofenac 0.1% ophthalmic solution in 2.5 mL and 5 mL bottles on back order and the company estimates a release date in early- to mid-April 2018.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=395>

**Bumetanide Injection****March 28, 2018**

## Reason for the Shortage

- Pfizer has bumetanide injection on shortage due to manufacturing delays.
- West-Ward did not provide a reason for the shortage.

## Estimated Resupply Dates



- Pfizer has bumetanide 0.25 mg/mL 4 mL and 10 mL vials on back order and the company estimates a release date of June 2019.
  - West-Ward has bumetanide 0.25 mg/mL 4 mL and 10 mL vials on a weekly allocation.
- <https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=307>

### Sodium Acetate Injection

**March 29, 2018**

#### Reason for the Shortage

- American Regent has had sodium acetate on long-term back order for several years.
- Fresenius Kabi had sodium acetate on shortage due to increased demand.
- Pfizer has sodium acetate on shortage due to manufacturing delays.

#### Estimated Resupply Dates

- All marketed presentations are available.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=317>

---